repligen  wikipedia repligen from wikipedia the free encyclopedia jump to navigation search repligen corporation type public company traded as nasdaq rgen sp  component industry pharmaceutical industry founded  founder alexander rich and paul schimmel headquarters waltham massachusetts united states key people walter c herlihy president ceo products materials used in the manufacture of biological drugs revenue us million operating income us million total assets us million total equity us million number of employees   website wwwrepligencom repligen repligen in the companys logo is an american company devoted to the development and production of materials used in the manufacture of biological drugs the company is based in waltham massachusetts and incorporated in delaware in  a public company repligen is listed on the nasdaq exchange under the symbol rgen as of february update repligen employed  people about  of these based in sweden contents  business model  sales and revenue  intellectual property  facilities  corporate history and governance  acquisitions and inlicensing  divestments and outlicensing  terminations and mothballing  financial history  products and services  notes  references business modeledit prior to  repligen maintained dual capabilities in the development of pharmaceutical therapeutics drug discovery and development and the development of materials supporting biological drug manufacture bioprocessing business a decision was made in  to focus on the bioprocessing business and reduce research and development expenditures in the period of  to  the majority of sales by the company were concentrated in the single protein a product line sales and revenueedit repligen employs a direct sales model to users of its products in the united states with some sales through intermediaries in certain foreign markets more than  of sales have been to customers in the united states and sweden during the  period longterm supply agreements have been established with major customers of the protein a products agreements which expire between  and  barring renegotiation as a result of royaltygenerating outlicensing royalty revenue from bristolmyers squibb has been in the  to  range as a proportion of total revenue during the  period in comparison to revenue from sales the largest customer accounted for  to  of revenue during the same period as a consequence of current operations about onethird each of revenue and cost and expenses are denominated in swedish krona currency the remaining twothirds denominated in united states dollars this presents an element risk to the business based on unpredictable fluctuations in currency exchange rates intellectual propertyedit the companys protein arelated offerings are supported by proprietary technology trade secrets and patent filings one patent was granted in april  and has been extended so that it remains in effect until  patents are pending on elements of the opus chromatography product line and enabling technology has been licensed from bioflash partners repligen retains an exclusive license to intellectual property owned by the university of michigan in relation to the orencia product divested to bristolmyers squibb facilitiesedit repligens company headquarters are housed together with its manufacturing facility in waltham massachusetts repligen maintains manufacturing facilities in waltham massachusetts and lund sweden growth factor products and the native form of protein a are manufactured in sweden recombinant forms of protein a are manufactured in both the united states and sweden assembly of the opus chromatography product line is done in the united states the lease on the main waltham facility extends through  a second smaller waltham facility was leased through the end of  and is now rented on a monthly basis in lund four buildings are under lease three expiring in mid and the fourth extending to late  corporate history and governanceedit alexander rich was a cofounder of repligen in  at the age of  dr rich is chairman emeritusof repligens board of directors dr rich had been a member of the board since  paul schimmel is also a cofounder of repligen in  at the age of  he is the ernest and jean hahn professor at the skaggs institute for chemical biology at the scripps research institute he used to be the john d and catherine t macarthur professor of biochemistry and biophysics in the department of biology at mit as of update the companys president and chief executive officer is walter c herlihy acquisitions and inlicensingedit in early  repligen licensed technology from bioflash which it subsequently incorporated into the opus line of prepackaged chromatography columns in  repligen acquired bioproduction assets from novozymes for  million which doubled the companys bioprocessing capabilities in december  the company acquired tangenx for  million divestments and outlicensingedit in  an agreement was struck to divest certain intellectual property rights to bristolmyers squibb around the drug orencia in exchange for ongoing royalty payments through the end of  at the end of  repligen outlicensed its spinal muscular atrophy program in particular the small molecule candidate drug rg to pfizer this divestment included licensing rights to two patents to pfizer at the start of  the company outlicensed its friedreichs ataxia program including a library of histone deacetylase inhibitor compounds to biomarin pharmaceutical for us and future milestone and royalty payments terminations and mothballingedit development of an imaging agent designated rg based on a synthetic human hormone was halted in  following a request by the usfda for additional safety and efficacy data beyond that provided in a new drug application nda submission a marketing authorization application had been submitted in parallel to the ema financial historyedit financials from  k     revenue     operating income     net income     total assets     total equity     products and servicesedit repligen is a major supplier of protein a both native and recombinant forms to the pharmaceutical industry in  protein a accounted for the majority of the companys product sales the company also provides growth factors to increase the productivity of cellbased bioproduction multiple alternating tangential flow atf systems and a line opus of chromatography columns scaled to manufacture of product for testing in clinical trials the opus product line contains a range of column sizes the size and composition of which are dependent upon customer requirements thus the full name of open platform user specified the smaller sizes of columns depend upon proprietary technology licensed from bioflash partners while the larger sizes are based on repligendeveloped proprietary technology notesedit  as of  the companys logo image can be found at httpwwwrepligencomsitesallthemesrepligenimageslogocorporategif   a b c d repligen  k  p   nasdaq rgen  a b c d e repligen  k  p   a b c d e f repligen  k  p   a b repligen  k  p   a b c d e repligen  k  p   a b c repligen  k  p   a b c repligen  k  p   repligen  k  p   b us  b  nucleic acids encoding recombinant protein a  us   methods of treating autoimmune disease via ctlaig  a b repligen  k  p   a b repligen  k  p   a b motley fool   forbes   httpwwwgenengnewscomgennewshighlightsrepligenacquirestangenxform  us   diaminoquinazolines for spinal muscular atrophy  us   diaminoquinazolines for spinal muscular atrophy  gen eng biotechnol news   repligen  k  p   values are presented in thousands of us dollars    million negative values appear in parentheses referencesedit forbes  alexander rich profiles forbes archived from the original on  march  retrieved  march   gen eng biotechnol news february   biomarin nabs repligens hdaci compound library news discovery  development gen eng biotechnol news paper   p   international new york times  repligen corporation business day international new york times company information archived from the original on  march  retrieved  march   motley fool  repligen corp key executives rgen the motley fool archived from the original on  march  retrieved  march   repligen corporation form k  sec documents form k repligen  commission file number  retrieved  march   street insider  september  repligen rgen replaces board member alex rich with alfred goldberg street insider archived from the original on  march  retrieved  march   retrieved from httpsenwikipediaorgwindexphptitlerepligenoldid categories manufacturing support companiescompanies based in massachusettscompanies listed on nasdaq establishments in massachusettshidden categories articles containing potentially dated statements from february all articles containing potentially dated statementsarticles containing potentially dated statements from  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view repligen  wikipedia repligen from wikipedia the free encyclopedia jump to navigation search repligen corporation type public company traded as nasdaq rgen sp  component industry pharmaceutical industry founded  founder alexander rich and paul schimmel headquarters waltham massachusetts united states key people walter c herlihy president ceo products materials used in the manufacture of biological drugs revenue us million operating income us million total assets us million total equity us million number of employees   website wwwrepligencom repligen repligen in the companys logo is an american company devoted to the development and production of materials used in the manufacture of biological drugs the company is based in waltham massachusetts and incorporated in delaware in  a public company repligen is listed on the nasdaq exchange under the symbol rgen as of february update repligen employed  people about  of these based in sweden contents  business model  sales and revenue  intellectual property  facilities  corporate history and governance  acquisitions and inlicensing  divestments and outlicensing  terminations and mothballing  financial history  products and services  notes  references business modeledit prior to  repligen maintained dual capabilities in the development of pharmaceutical therapeutics drug discovery and development and the development of materials supporting biological drug manufacture bioprocessing business a decision was made in  to focus on the bioprocessing business and reduce research and development expenditures in the period of  to  the majority of sales by the company were concentrated in the single protein a product line sales and revenueedit repligen employs a direct sales model to users of its products in the united states with some sales through intermediaries in certain foreign markets more than  of sales have been to customers in the united states and sweden during the  period longterm supply agreements have been established with major customers of the protein a products agreements which expire between  and  barring renegotiation as a result of royaltygenerating outlicensing royalty revenue from bristolmyers squibb has been in the  to  range as a proportion of total revenue during the  period in comparison to revenue from sales the largest customer accounted for  to  of revenue during the same period as a consequence of current operations about onethird each of revenue and cost and expenses are denominated in swedish krona currency the remaining twothirds denominated in united states dollars this presents an element risk to the business based on unpredictable fluctuations in currency exchange rates intellectual propertyedit the companys protein arelated offerings are supported by proprietary technology trade secrets and patent filings one patent was granted in april  and has been extended so that it remains in effect until  patents are pending on elements of the opus chromatography product line and enabling technology has been licensed from bioflash partners repligen retains an exclusive license to intellectual property owned by the university of michigan in relation to the orencia product divested to bristolmyers squibb facilitiesedit repligens company headquarters are housed together with its manufacturing facility in waltham massachusetts repligen maintains manufacturing facilities in waltham massachusetts and lund sweden growth factor products and the native form of protein a are manufactured in sweden recombinant forms of protein a are manufactured in both the united states and sweden assembly of the opus chromatography product line is done in the united states the lease on the main waltham facility extends through  a second smaller waltham facility was leased through the end of  and is now rented on a monthly basis in lund four buildings are under lease three expiring in mid and the fourth extending to late  corporate history and governanceedit alexander rich was a cofounder of repligen in  at the age of  dr rich is chairman emeritusof repligens board of directors dr rich had been a member of the board since  paul schimmel is also a cofounder of repligen in  at the age of  he is the ernest and jean hahn professor at the skaggs institute for chemical biology at the scripps research institute he used to be the john d and catherine t macarthur professor of biochemistry and biophysics in the department of biology at mit as of update the companys president and chief executive officer is walter c herlihy acquisitions and inlicensingedit in early  repligen licensed technology from bioflash which it subsequently incorporated into the opus line of prepackaged chromatography columns in  repligen acquired bioproduction assets from novozymes for  million which doubled the companys bioprocessing capabilities in december  the company acquired tangenx for  million divestments and outlicensingedit in  an agreement was struck to divest certain intellectual property rights to bristolmyers squibb around the drug orencia in exchange for ongoing royalty payments through the end of  at the end of  repligen outlicensed its spinal muscular atrophy program in particular the small molecule candidate drug rg to pfizer this divestment included licensing rights to two patents to pfizer at the start of  the company outlicensed its friedreichs ataxia program including a library of histone deacetylase inhibitor compounds to biomarin pharmaceutical for us and future milestone and royalty payments terminations and mothballingedit development of an imaging agent designated rg based on a synthetic human hormone was halted in  following a request by the usfda for additional safety and efficacy data beyond that provided in a new drug application nda submission a marketing authorization application had been submitted in parallel to the ema financial historyedit financials from  k     revenue     operating income     net income     total assets     total equity     products and servicesedit repligen is a major supplier of protein a both native and recombinant forms to the pharmaceutical industry in  protein a accounted for the majority of the companys product sales the company also provides growth factors to increase the productivity of cellbased bioproduction multiple alternating tangential flow atf systems and a line opus of chromatography columns scaled to manufacture of product for testing in clinical trials the opus product line contains a range of column sizes the size and composition of which are dependent upon customer requirements thus the full name of open platform user specified the smaller sizes of columns depend upon proprietary technology licensed from bioflash partners while the larger sizes are based on repligendeveloped proprietary technology notesedit  as of  the companys logo image can be found at httpwwwrepligencomsitesallthemesrepligenimageslogocorporategif   a b c d repligen  k  p   nasdaq rgen  a b c d e repligen  k  p   a b c d e f repligen  k  p   a b repligen  k  p   a b c d e repligen  k  p   a b c repligen  k  p   a b c repligen  k  p   repligen  k  p   b us  b  nucleic acids encoding recombinant protein a  us   methods of treating autoimmune disease via ctlaig  a b repligen  k  p   a b repligen  k  p   a b motley fool   forbes   httpwwwgenengnewscomgennewshighlightsrepligenacquirestangenxform  us   diaminoquinazolines for spinal muscular atrophy  us   diaminoquinazolines for spinal muscular atrophy  gen eng biotechnol news   repligen  k  p   values are presented in thousands of us dollars    million negative values appear in parentheses referencesedit forbes  alexander rich profiles forbes archived from the original on  march  retrieved  march   gen eng biotechnol news february   biomarin nabs repligens hdaci compound library news discovery  development gen eng biotechnol news paper   p   international new york times  repligen corporation business day international new york times company information archived from the original on  march  retrieved  march   motley fool  repligen corp key executives rgen the motley fool archived from the original on  march  retrieved  march   repligen corporation form k  sec documents form k repligen  commission file number  retrieved  march   street insider  september  repligen rgen replaces board member alex rich with alfred goldberg street insider archived from the original on  march  retrieved  march   retrieved from httpsenwikipediaorgwindexphptitlerepligenoldid categories manufacturing support companiescompanies based in massachusettscompanies listed on nasdaq establishments in massachusettshidden categories articles containing potentially dated statements from february all articles containing potentially dated statementsarticles containing potentially dated statements from  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view repligen  wikipedia repligen from wikipedia the free encyclopedia jump to navigation search repligen corporation type public company traded as nasdaq rgen sp  component industry pharmaceutical industry founded  founder alexander rich and paul schimmel headquarters waltham massachusetts united states key people walter c herlihy president ceo products materials used in the manufacture of biological drugs revenue us million operating income us million total assets us million total equity us million number of employees   website wwwrepligencom repligen repligen in the companys logo is an american company devoted to the development and production of materials used in the manufacture of biological drugs the company is based in waltham massachusetts and incorporated in delaware in  a public company repligen is listed on the nasdaq exchange under the symbol rgen as of february update repligen employed  people about  of these based in sweden contents  business model  sales and revenue  intellectual property  facilities  corporate history and governance  acquisitions and inlicensing  divestments and outlicensing  terminations and mothballing  financial history  products and services  notes  references business modeledit prior to  repligen maintained dual capabilities in the development of pharmaceutical therapeutics drug discovery and development and the development of materials supporting biological drug manufacture bioprocessing business a decision was made in  to focus on the bioprocessing business and reduce research and development expenditures in the period of  to  the majority of sales by the company were concentrated in the single protein a product line sales and revenueedit repligen employs a direct sales model to users of its products in the united states with some sales through intermediaries in certain foreign markets more than  of sales have been to customers in the united states and sweden during the  period longterm supply agreements have been established with major customers of the protein a products agreements which expire between  and  barring renegotiation as a result of royaltygenerating outlicensing royalty revenue from bristolmyers squibb has been in the  to  range as a proportion of total revenue during the  period in comparison to revenue from sales the largest customer accounted for  to  of revenue during the same period as a consequence of current operations about onethird each of revenue and cost and expenses are denominated in swedish krona currency the remaining twothirds denominated in united states dollars this presents an element risk to the business based on unpredictable fluctuations in currency exchange rates intellectual propertyedit the companys protein arelated offerings are supported by proprietary technology trade secrets and patent filings one patent was granted in april  and has been extended so that it remains in effect until  patents are pending on elements of the opus chromatography product line and enabling technology has been licensed from bioflash partners repligen retains an exclusive license to intellectual property owned by the university of michigan in relation to the orencia product divested to bristolmyers squibb facilitiesedit repligens company headquarters are housed together with its manufacturing facility in waltham massachusetts repligen maintains manufacturing facilities in waltham massachusetts and lund sweden growth factor products and the native form of protein a are manufactured in sweden recombinant forms of protein a are manufactured in both the united states and sweden assembly of the opus chromatography product line is done in the united states the lease on the main waltham facility extends through  a second smaller waltham facility was leased through the end of  and is now rented on a monthly basis in lund four buildings are under lease three expiring in mid and the fourth extending to late  corporate history and governanceedit alexander rich was a cofounder of repligen in  at the age of  dr rich is chairman emeritusof repligens board of directors dr rich had been a member of the board since  paul schimmel is also a cofounder of repligen in  at the age of  he is the ernest and jean hahn professor at the skaggs institute for chemical biology at the scripps research institute he used to be the john d and catherine t macarthur professor of biochemistry and biophysics in the department of biology at mit as of update the companys president and chief executive officer is walter c herlihy acquisitions and inlicensingedit in early  repligen licensed technology from bioflash which it subsequently incorporated into the opus line of prepackaged chromatography columns in  repligen acquired bioproduction assets from novozymes for  million which doubled the companys bioprocessing capabilities in december  the company acquired tangenx for  million divestments and outlicensingedit in  an agreement was struck to divest certain intellectual property rights to bristolmyers squibb around the drug orencia in exchange for ongoing royalty payments through the end of  at the end of  repligen outlicensed its spinal muscular atrophy program in particular the small molecule candidate drug rg to pfizer this divestment included licensing rights to two patents to pfizer at the start of  the company outlicensed its friedreichs ataxia program including a library of histone deacetylase inhibitor compounds to biomarin pharmaceutical for us and future milestone and royalty payments terminations and mothballingedit development of an imaging agent designated rg based on a synthetic human hormone was halted in  following a request by the usfda for additional safety and efficacy data beyond that provided in a new drug application nda submission a marketing authorization application had been submitted in parallel to the ema financial historyedit financials from  k     revenue     operating income     net income     total assets     total equity     products and servicesedit repligen is a major supplier of protein a both native and recombinant forms to the pharmaceutical industry in  protein a accounted for the majority of the companys product sales the company also provides growth factors to increase the productivity of cellbased bioproduction multiple alternating tangential flow atf systems and a line opus of chromatography columns scaled to manufacture of product for testing in clinical trials the opus product line contains a range of column sizes the size and composition of which are dependent upon customer requirements thus the full name of open platform user specified the smaller sizes of columns depend upon proprietary technology licensed from bioflash partners while the larger sizes are based on repligendeveloped proprietary technology notesedit  as of  the companys logo image can be found at httpwwwrepligencomsitesallthemesrepligenimageslogocorporategif   a b c d repligen  k  p   nasdaq rgen  a b c d e repligen  k  p   a b c d e f repligen  k  p   a b repligen  k  p   a b c d e repligen  k  p   a b c repligen  k  p   a b c repligen  k  p   repligen  k  p   b us  b  nucleic acids encoding recombinant protein a  us   methods of treating autoimmune disease via ctlaig  a b repligen  k  p   a b repligen  k  p   a b motley fool   forbes   httpwwwgenengnewscomgennewshighlightsrepligenacquirestangenxform  us   diaminoquinazolines for spinal muscular atrophy  us   diaminoquinazolines for spinal muscular atrophy  gen eng biotechnol news   repligen  k  p   values are presented in thousands of us dollars    million negative values appear in parentheses referencesedit forbes  alexander rich profiles forbes archived from the original on  march  retrieved  march   gen eng biotechnol news february   biomarin nabs repligens hdaci compound library news discovery  development gen eng biotechnol news paper   p   international new york times  repligen corporation business day international new york times company information archived from the original on  march  retrieved  march   motley fool  repligen corp key executives rgen the motley fool archived from the original on  march  retrieved  march   repligen corporation form k  sec documents form k repligen  commission file number  retrieved  march   street insider  september  repligen rgen replaces board member alex rich with alfred goldberg street insider archived from the original on  march  retrieved  march   retrieved from httpsenwikipediaorgwindexphptitlerepligenoldid categories manufacturing support companiescompanies based in massachusettscompanies listed on nasdaq establishments in massachusettshidden categories articles containing potentially dated statements from february all articles containing potentially dated statementsarticles containing potentially dated statements from  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view repligen corp rgeno company profile  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states profile repligen corp rgeno related topics stocksstock screenerhealthcarepharmaceuticals overview news key developments people charts financials analysts research pulse rgeno on nasdaq usd  jul  change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  full description repligen corporation incorporated on may   is a bioprocessing company the company is focused on the development manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process the companys portfolio includes protein products chromatography products and filtration products the companys bioprocessing products are sold to life sciences companies biopharmaceutical development companies and contract manufacturing organizations across the world the protein a ligands and growth factor products that the company manufactures are components of chromatography resins and cell culture media respectivelyprotein productsthe company is a provider of protein a ligands a component of protein a chromatography resins media used in the purification of virtually all monoclonal antibody mabbased drugs on the market or in development the company manufactures multiple forms of protein a ligands as of december   the company had two manufacturing sites one in lund sweden and another in waltham massachusettschromatography productsthe companys chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs its other products include protein a chromatography resins used in a small number of commercial drug processes and enzymelinked immunosorbent assay elisa test kits used by quality control departments to detect and measure the presence of leached protein a andor growth factor in the final product its opus prepacked chromatography columns ppcs are used in the purification of clinicalstage biologics chromatography columns packed with chromatography media are used in biomanufacturing to purify the biological drugs once separated typically using filtration technology from the contents of a bioreactorfiltration productsthe companys filtration products include xcell alternating tangential flow atf systems and sius tangential flow filtration tff cassettes the xcell atf system is a filtration device used in upstream processes to continuously remove cellular metabolic waste products during the course of a fermentation run freeing healthy cells to continue producing the biologic drug of interest xcell atf systems consist of either a stainless steel or plastic housing that contains a hollowfiber filter plus an associated pump and controller sius tff cassettes are used to concentrate clinical and commercialstage biologic drugs » full overview of rgeno company address repligen corp  seyon st bldg  ste waltham   ma    p f  company web links home page officers  directors name compensation karen dawes  tony hunt  jon snodgres  howard benjamin  nicolas barthelemy  » more officers  directors repligen corp news briefrepligen prices public offering of shares of common stock jun   briefrepligen corp announces proposed public offering of shares of common stock jun   briefrepligen and spectrum to join forces jun   briefrepligen posts q adj earnings per share  feb   » more rgeno news related topics stocksstock screenerhealthcarepharmaceuticals repligen corporation competitors  nasdaqcom hot topics etfs  smart portfolio  currencies  online broker center search home  quotes  rgen  competitors repligen corporation competitors       get rgen alerts delayed  data as of jul      find a broker to begin trading rgen now exchangenasdaq industry health care community rating view    rgen premarket rgen     edit symbol list symbol lookup real time nls trade reporting flashquotes infoquotes summary quote charts interactive charts premarket charts after hours charts revenue  eps summary company financials  view competitors  short interest company news press releases company news press releases sentiment analyst stock research stock report sec filings  holdingsinsider summary  institutional holdings  insider form  equity options premarket quotes after hours quotes company research  stockconsultant stock comparison  guru analysis annual report historical quotes call transcripts dividend history lynch analysis graham analysis validea momentum analysis fool analysis dreman analysis zweig analysis fisher analysis oshaughnessy analysis etf detail etf profile comparison charts symbol list views flashquotes infoquotes stock details summary quote realtime quote after hours quote premarket quote historical quote option chain charts basic chart interactive chart company news company headlines press releases market stream stock analysis analyst research guru analysis stock report competitors stock consultant stock comparison fundamentals call transcripts annual report income statement revenueeps sec filings short interest dividend history holdings ownership summary institutional holdings insiderssec form  closex edit symbol list enter up to  symbols separated by commas or spaces in the text box below these symbols will be available during your session for use on applicable pages go now clear list dont know the stock symbol use the symbol lookup tool alphabetize the sort order of my symbols closex   symbol lookup closex investing just got easier… sign up now to become a nasdaqcom member and begin receiving instant notifications when key events occur that affect the stocks you follow access now  save stocks competitor industry biotechnology biological products no diagnostic substances repligen corporation companyname ▲ symbol market lastsale netchange volume todays high  low  weeks high  low p  e ratio market cap acceleron pharma incxlrn nasdaqgm    ▼        ne  acorda therapeutics incacor nasdaqgs    ▼        ne  adaptimmune therapeutics plcadap nasdaqgs    ▼        ne  adma biologics incadma nasdaqcm    ▼        ne  adverum biotechnologies incadvm nasdaqgm    ▼        ne  aerie pharmaceuticals incaeri nasdaqgm    ▼        ne  aevi genomic medicine incgnmx nasdaqgm    ▼        ne  agenus incagen nasdaqcm    ▼        ne  amgen incamgn nasdaqgs    ▼          ampliphi biosciences corporationaphb amex    ▼        ne  apollo endosurgery incapen nasdaqgm    ▼        ne  applied genetic technologies corporationagtc nasdaqgm    ▼          aptose biosciences incapto nasdaqcm    ▼        ne  argenx seargx nasdaqgs    ▼        ne  asterias biotherapeutics incast amex    ▼        ne  atara biotherapeutics incatra nasdaqgs    ▼        ne  atyr pharma inclife nasdaqgs    ▼        ne  audentes therapeutics incbold nasdaqgm    ▼        ne  avexis incavxs nasdaqgs    ▼        ne  aviragen therapeutics incavir nasdaqgs    ▼        ne  biocryst pharmaceuticals incbcrx nasdaqgs    ▲        ne  biogen incbiib nasdaqgs    ▼          biondvax pharmaceuticals ltdbvxv nasdaqcm    ▼        ne  biondvax pharmaceuticals ltdbvxvw nasdaqcm    ▼        ne  biotechne corptech nasdaqgs    ▼           first previousnext last  closex edit favorites enter up to  symbols separated by commas or spaces in the text box below these symbols will be available during your session for use on applicable pages update clear list closex customize your nasdaqcom experience background color selector select the background color of your choice  black  slate gray  light gray  gray blue quote search select a default target page for your quote search  realtime  after hours  premarket  news  flash quote  summary quote  interactive charts  default setting please note that once you make your selection it will apply to all future visits to nasdaqcom if at any time you are interested in reverting to our default settings please select default setting above if you have any questions or encounter any issues in changing your default settings please email isfeedbacknasdaqcom closex please confirm your selection you have selected to change your default setting for the quote search this will now be your default target page unless you change your configuration again or you delete your cookies are you sure you want to change your settings yes no closex please disable your ad blocker or update your settings to ensure that javascript and cookies are enabled so that we can continue to provide you with the firstrate market news and data youve come to expect from us closex repligen  wikipedia repligen from wikipedia the free encyclopedia jump to navigation search repligen corporation type public company traded as nasdaq rgen sp  component industry pharmaceutical industry founded  founder alexander rich and paul schimmel headquarters waltham massachusetts united states key people walter c herlihy president ceo products materials used in the manufacture of biological drugs revenue us million operating income us million total assets us million total equity us million number of employees   website wwwrepligencom repligen repligen in the companys logo is an american company devoted to the development and production of materials used in the manufacture of biological drugs the company is based in waltham massachusetts and incorporated in delaware in  a public company repligen is listed on the nasdaq exchange under the symbol rgen as of february update repligen employed  people about  of these based in sweden contents  business model  sales and revenue  intellectual property  facilities  corporate history and governance  acquisitions and inlicensing  divestments and outlicensing  terminations and mothballing  financial history  products and services  notes  references business modeledit prior to  repligen maintained dual capabilities in the development of pharmaceutical therapeutics drug discovery and development and the development of materials supporting biological drug manufacture bioprocessing business a decision was made in  to focus on the bioprocessing business and reduce research and development expenditures in the period of  to  the majority of sales by the company were concentrated in the single protein a product line sales and revenueedit repligen employs a direct sales model to users of its products in the united states with some sales through intermediaries in certain foreign markets more than  of sales have been to customers in the united states and sweden during the  period longterm supply agreements have been established with major customers of the protein a products agreements which expire between  and  barring renegotiation as a result of royaltygenerating outlicensing royalty revenue from bristolmyers squibb has been in the  to  range as a proportion of total revenue during the  period in comparison to revenue from sales the largest customer accounted for  to  of revenue during the same period as a consequence of current operations about onethird each of revenue and cost and expenses are denominated in swedish krona currency the remaining twothirds denominated in united states dollars this presents an element risk to the business based on unpredictable fluctuations in currency exchange rates intellectual propertyedit the companys protein arelated offerings are supported by proprietary technology trade secrets and patent filings one patent was granted in april  and has been extended so that it remains in effect until  patents are pending on elements of the opus chromatography product line and enabling technology has been licensed from bioflash partners repligen retains an exclusive license to intellectual property owned by the university of michigan in relation to the orencia product divested to bristolmyers squibb facilitiesedit repligens company headquarters are housed together with its manufacturing facility in waltham massachusetts repligen maintains manufacturing facilities in waltham massachusetts and lund sweden growth factor products and the native form of protein a are manufactured in sweden recombinant forms of protein a are manufactured in both the united states and sweden assembly of the opus chromatography product line is done in the united states the lease on the main waltham facility extends through  a second smaller waltham facility was leased through the end of  and is now rented on a monthly basis in lund four buildings are under lease three expiring in mid and the fourth extending to late  corporate history and governanceedit alexander rich was a cofounder of repligen in  at the age of  dr rich is chairman emeritusof repligens board of directors dr rich had been a member of the board since  paul schimmel is also a cofounder of repligen in  at the age of  he is the ernest and jean hahn professor at the skaggs institute for chemical biology at the scripps research institute he used to be the john d and catherine t macarthur professor of biochemistry and biophysics in the department of biology at mit as of update the companys president and chief executive officer is walter c herlihy acquisitions and inlicensingedit in early  repligen licensed technology from bioflash which it subsequently incorporated into the opus line of prepackaged chromatography columns in  repligen acquired bioproduction assets from novozymes for  million which doubled the companys bioprocessing capabilities in december  the company acquired tangenx for  million divestments and outlicensingedit in  an agreement was struck to divest certain intellectual property rights to bristolmyers squibb around the drug orencia in exchange for ongoing royalty payments through the end of  at the end of  repligen outlicensed its spinal muscular atrophy program in particular the small molecule candidate drug rg to pfizer this divestment included licensing rights to two patents to pfizer at the start of  the company outlicensed its friedreichs ataxia program including a library of histone deacetylase inhibitor compounds to biomarin pharmaceutical for us and future milestone and royalty payments terminations and mothballingedit development of an imaging agent designated rg based on a synthetic human hormone was halted in  following a request by the usfda for additional safety and efficacy data beyond that provided in a new drug application nda submission a marketing authorization application had been submitted in parallel to the ema financial historyedit financials from  k     revenue     operating income     net income     total assets     total equity     products and servicesedit repligen is a major supplier of protein a both native and recombinant forms to the pharmaceutical industry in  protein a accounted for the majority of the companys product sales the company also provides growth factors to increase the productivity of cellbased bioproduction multiple alternating tangential flow atf systems and a line opus of chromatography columns scaled to manufacture of product for testing in clinical trials the opus product line contains a range of column sizes the size and composition of which are dependent upon customer requirements thus the full name of open platform user specified the smaller sizes of columns depend upon proprietary technology licensed from bioflash partners while the larger sizes are based on repligendeveloped proprietary technology notesedit  as of  the companys logo image can be found at httpwwwrepligencomsitesallthemesrepligenimageslogocorporategif   a b c d repligen  k  p   nasdaq rgen  a b c d e repligen  k  p   a b c d e f repligen  k  p   a b repligen  k  p   a b c d e repligen  k  p   a b c repligen  k  p   a b c repligen  k  p   repligen  k  p   b us  b  nucleic acids encoding recombinant protein a  us   methods of treating autoimmune disease via ctlaig  a b repligen  k  p   a b repligen  k  p   a b motley fool   forbes   httpwwwgenengnewscomgennewshighlightsrepligenacquirestangenxform  us   diaminoquinazolines for spinal muscular atrophy  us   diaminoquinazolines for spinal muscular atrophy  gen eng biotechnol news   repligen  k  p   values are presented in thousands of us dollars    million negative values appear in parentheses referencesedit forbes  alexander rich profiles forbes archived from the original on  march  retrieved  march   gen eng biotechnol news february   biomarin nabs repligens hdaci compound library news discovery  development gen eng biotechnol news paper   p   international new york times  repligen corporation business day international new york times company information archived from the original on  march  retrieved  march   motley fool  repligen corp key executives rgen the motley fool archived from the original on  march  retrieved  march   repligen corporation form k  sec documents form k repligen  commission file number  retrieved  march   street insider  september  repligen rgen replaces board member alex rich with alfred goldberg street insider archived from the original on  march  retrieved  march   retrieved from httpsenwikipediaorgwindexphptitlerepligenoldid categories manufacturing support companiescompanies based in massachusettscompanies listed on nasdaq establishments in massachusettshidden categories articles containing potentially dated statements from february all articles containing potentially dated statementsarticles containing potentially dated statements from  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view stocks index  markets index bulletin investor alert new york markets open in market snapshot analyst ratings stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest astarbucks stock price target cut to  from  at jp morgan agoodyear tires stock dives after slashed profit outlook offsets inline earnings awatch out ‘kids’ are making the most money in this stock market astock market set to extend fresh tech rout as amazon disappoints gdp data ahead ashares of video game maker activision blizzard down more than  aintel earnings have message for amd and nvidia ‘bring it on’ aaarons shares up nearly  in friday premarket trading aamazon’s freespending ways hit earnings but don’t expect a shift to thrift aabbvie shares up  in premarket trade aabbvie still sees fullyear adj eps  to  aabbvie still sees fullyear eps  to  aabbvie q revenue  bln vs  bln factset consensus  bln aabbvie q adj eps  factset consensus  agoodyears stock plunges  premarket after q results aabbvie q eps  vs  cents agoodyear cuts  segment operating income outlook to  bln bln from  bln aget ready for the lessprofitable amazon that you used to know awells fargo charged customers for duplicate car insurance agoodyear q sales  bln vs  bln factset consensus  bln acorrect goodyear q adj eps  cents factset consensus  cents loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  rgen stock price  repligen corp stock quote us nasdaq  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y djia f    sp f    nasdaq f    gold    silver    crude oil    sp  movers adp  tsco  vz  orly  ca  jci  ffiv  xl  latest newsall times eastern a starbucks stock price target cut to  from  at jp morgan a goodyear tires stock dives after slashed profit outlook offsets inline earnings a opinion watch out ‘kids’ are making the most money in this stock market a updated stock market set to extend fresh tech rout as amazon disappoints gdp data ahead a shares of video game maker activision blizzard down more than  a updated intel earnings have message for amd and nvidia ‘bring it on’ a aarons shares up nearly  in friday premarket trading a updated amazon’s freespending ways hit earnings but don’t expect a shift to thrift a abbvie shares up  in premarket trade a abbvie still sees fullyear adj eps  to  to be replaced home investing quotes stocks united states rgen overview compare quotes stock screener earnings calendar sectors nasdaq rgen us nasdaq join td ameritrade find a broker repligen corp watchlist creatergenalert after hours last updated jul    pm edt delayed quote     after hours volume k close chg chg     advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume k  day avg  k open  close   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap b shares outstanding m public float m beta  rev per employee k pe ratio  eps  yield na dividend na exdividend date na short interest m   of float shorted  average volume k performance  day   month   month  ytd   year  recent news marketwatch other dow jones repligen stock fair value estimate raised to  from  at janney repligen stock fair value estimate raised to  from  at janney jun   at  am et by tomi kilgore repligen to buy filtration company spectrum for  million in cash and stock repligen corp announced friday an agreement to buy privatelyheld filtration company spectrum inc for about  million under terms of the deal repligen will pay  million in cash and  million shares of its stock which represents about  of the shares outstanding repligen expects the deal to be completed during the third quarter of  and add  million to  million to repligens  revenue the deal is expected to add to earnings in  this is a pivotal transaction for repligen that meets all of our acquisition criteria and is a major step forward in building repligen as a global leader in bioprocessing and achieving our long term financial goals said repligen chief executive tony hunt the stock which was still inactive in premarket trade has rallied  year to date while the sp  has gained  jun   at  am et by tomi kilgore repligen agrees to buy spectrum in a cashandstock deal valued at  mln repligen agrees to buy spectrum in a cashandstock deal valued at  mln jun   at  am et by tomi kilgore repligens stock was inactive premarket prior to trading halt repligens stock was inactive premarket prior to trading halt jun   at  am et by tomi kilgore repligens stock halted for news pending repligens stock halted for news pending jun   at  am et by tomi kilgore market sends a message cash is king jun   at  pm et by kevin marder cash aint trash as the stock market behaves bearishly may   at  pm et by kevin marder nasdaq still has many opportunities for speculators apr   at  pm et by kevin marder bull trend absorbs soft secondquarter start apr   at  am et by michael ashbaugh these are the most profitable nasdaq biotech companies mar   at  am et by philip van doorn here are the bestperforming stocks so far in  jan   at  am et by philip van doorn speculators live by the sword die by the sword jul   at  pm et by kevin marder repligen corp up  in premarket jan   at  am et by steve gelsi friday’s biggest gaining and declining stocks jun   at  pm et by marketwatch repligen fda wants more trials for secretin drug jun   at  pm et fda gives repligens secreflo priority status feb   at  am et repligen receives fasttrack designation from fda jun   at  am et sanofi regeneron report progress with cancer drug jun   at  am et by robert daniel monday’s biggest gaining and declining stocks mar   at  pm et by christopher hinton repligen paces downturn in biotech stocks mar   at  pm et by wallace witkowski investing from the ground up sep   at  am et on barrons between friends former merck analyst is charged with insider trading oct   at  am et on the wall street journal cfo moves repligen corp top image systems ltd jul   at  pm et on the wall street journal cfo moves microvision progenics repligen sep   at  pm et on the wall street journal stocks to watch morgan stanley darden restaurants ryder system jun   at  am et on the wall street journal valassis communications repligen biggest price decliners vci rgen apr   at  pm et on the wall street journal valassis communications repligen biggest price decliners vci rgen apr   at  pm et on the wall street journal repligen says fda cancels meeting on new drug apr   at  am et on the wall street journal neophotonics repligen biggest price decliners nptn rgen mar   at  pm et on the wall street journal stocks notch a down day on oil jitters mar   at  am et on the wall street journal movado group repligen biggest price decliners mov rgen dec   at  pm et on the wall street journal columbia bancorp sags  nutrisystem gains apr   at  pm et on the wall street journal krispy kreme doughnuts repligen biggest price decliners kkd rgen sep   at  pm et on the wall street journal bearingpoint repligen biggest price decliners be rgen sep   at  pm et on the wall street journal july was a loser for small stocks aug   at  am et on the wall street journal bristolmyerss puts are active jan   at  am et on the wall street journal repligen mit sue imclone may   at  pm et on the wall street journal autism drug secretin fails in trial jan   at  am et on the wall street journal russell  jumps aided by tech jan   at  pm et on the wall street journal repligen lacks evidence in patent case sep   at  pm et on the wall street journal recent news other news press releases benin management corp buys prudential financial inc united parcel service inc chevron corp  benin management corp buys prudential financial inc united parcel service inc chevron corp sells metlife inc unitedhealth group inc parker hannifin corp jul   at  pm et on gurufocuscom top  healthcare penny stocks for  these three penny health care stocks are poised for a positive  jul   at  am et on investopediacom top ranked momentum stocks to buy for july rd here are four stocks with buy rank and strong momentum characteristics for investors to consider today july rd jul   at  am et on zackscom repligen spectrum purchase makes sense but leaves shares more than fully valued repligen spectrum purchase makes sense but leaves shares more than fully valued jun   at  pm et on seeking alpha repligen to merge with spectrum in m deal repligen to merge with spectrum in m deal jun   at  am et on seeking alpha repligen corporation rgen bank of america merrill lynch  health care conference  slideshow repligen corporation rgen bank of america merrill lynch  health care conference  slideshow may   at  pm et on seeking alpha repligens rgen ceo tony hunt on q  results  earnings call transcript repligens rgen ceo tony hunt on q  results  earnings call transcript may   at  pm et on seeking alpha trade of the day repligen nasdaqrgen trade of the day repligen nasdaqrgen may   at  am et on investorplacecom q repligen corp q repligen corp may   at  pm et on edgar online  edg  q k solaris asset management llc buys ishares core sp midcap berkshire hathaway inc  solaris asset management llc buys ishares core sp midcap berkshire hathaway inc vanguard sp  sells ishares core sp smallcap general electric co ishares sp midcap  growth may   at  pm et on gurufocuscom notable earnings before thursday’s open notable earnings before thursday’s open may   at  pm et on seeking alpha premarket analyst action  healthcare apr   at  am et on seeking alpha repligens rgen ceo tony hunt on q  results  earnings call transcript feb   at  pm et on seeking alpha repligen revenues up  nongaap eps up  in fy updates guidance feb   at  am et on seeking alpha  a record year jan   at  am et on seeking alpha repligen corporation rgen presents at th annual jp morgan healthcare conference jan   at  am et on seeking alpha the zacks analyst blog highlights sucampo pharmaceuticals dr reddys laboratories biomarin pharmaceutical and repligen jan   at  am et on zackscom  overlooked drug stocks to watch out for in  jan   at  am et on zackscom  biotechnology stocks to sell now dec   at  am et on investorplacecom repligen buys tangenx technology expected to be accretive to eps in  dec   at  am et on seeking alpha repligen to report second quarter  financial results repligen to report second quarter  financial results jul   at  am et on globenewswire repligen corporation prices public offering of shares of common stock repligen corporation prices public offering of shares of common stock jun   at  pm et on globenewswire repligen corporation announces proposed public offering of shares of common stock repligen corporation announces proposed public offering of shares of common stock jun   at  pm et on globenewswire corporate news blog  repligen corp and spectrum merge to form leader in filtration for bioprocessing industry corporate news blog  repligen corp and spectrum merge to form leader in filtration for bioprocessing industry jun   at  am et on accesswire repligen corporation and spectrum inc to join forces repligen corporation and spectrum inc to join forces jun   at  am et on globenewswire repligen to present at jefferies  global annual healthcare conference repligen to present at jefferies  global annual healthcare conference may   at  am et on globenewswire repligen to participate in th annual craighallum institutional investor conference repligen to participate in th annual craighallum institutional investor conference may   at  am et on globenewswire repligen to present at bank of america merrill lynch  healthcare conference repligen to present at bank of america merrill lynch  healthcare conference may   at  pm et on globenewswire repligen reports first quarter  financial results repligen reports first quarter  financial results may   at  am et on globenewswire investor network repligen corporation to host earnings call investor network repligen corporation to host earnings call may   at  am et on accesswire repligen to report first quarter  financial results apr   at  am et on globenewswire repligen reports fourth quarter  financial results provides guidance for  feb   at  am et on globenewswire repligen to report fourth quarter and full year  financial results provides financial guidance for  feb   at  pm et on globenewswire repligen to present at th annual jp morgan healthcare conference jan   at  am et on globenewswire blog coverage repligen acquires maker of tangential flow filtration cassettes dec   at  am et on accesswire update  repligen acquires tangenx technology corporation dec   at  am et on globenewswire repligen acquires tangenx technology corporation dec   at  am et on globenewswire prepacked chromatography columns market  global industry analysis size share growth trends and forecast    nov   at  pm et on pr newswire  prf repligen to participate in stephens inc fall investment conference  nov   at  am et on globenewswire repligen to report third quarter  financial results oct   at  am et on globenewswire repligen corp repligen corp engages on the development production and commercialization of products used in the process of manufacturing biological drugs it offers upstream solutions downstream solutions and analytics the upstream solutions offers xcell atf system and cell culture supplements the downstream solutions includes opus prepackaged chromatography columns protein a affinity resins and protein a ligands the analytics involves elisa kits the company was founded by alexander g rich in may  and is headquartered in waltham ma see full profile analyst ratings sell under hold over buy number of ratings  full ratings benzingas top initiations feb   at  am et on benzingacom competitors name chg  market cap novavax inc  m neurocrine biosciences inc  b biomarin pharmaceutical inc  b sangamo therapeutics inc  m bristolmyers squibb co  b competitor data provided by partner content trending tickers powered by amzn  spy  uvxy  aapl  qqq  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience repligen  wikipedia repligen from wikipedia the free encyclopedia jump to navigation search repligen corporation type public company traded as nasdaq rgen sp  component industry pharmaceutical industry founded  founder alexander rich and paul schimmel headquarters waltham massachusetts united states key people walter c herlihy president ceo products materials used in the manufacture of biological drugs revenue us million operating income us million total assets us million total equity us million number of employees   website wwwrepligencom repligen repligen in the companys logo is an american company devoted to the development and production of materials used in the manufacture of biological drugs the company is based in waltham massachusetts and incorporated in delaware in  a public company repligen is listed on the nasdaq exchange under the symbol rgen as of february update repligen employed  people about  of these based in sweden contents  business model  sales and revenue  intellectual property  facilities  corporate history and governance  acquisitions and inlicensing  divestments and outlicensing  terminations and mothballing  financial history  products and services  notes  references business modeledit prior to  repligen maintained dual capabilities in the development of pharmaceutical therapeutics drug discovery and development and the development of materials supporting biological drug manufacture bioprocessing business a decision was made in  to focus on the bioprocessing business and reduce research and development expenditures in the period of  to  the majority of sales by the company were concentrated in the single protein a product line sales and revenueedit repligen employs a direct sales model to users of its products in the united states with some sales through intermediaries in certain foreign markets more than  of sales have been to customers in the united states and sweden during the  period longterm supply agreements have been established with major customers of the protein a products agreements which expire between  and  barring renegotiation as a result of royaltygenerating outlicensing royalty revenue from bristolmyers squibb has been in the  to  range as a proportion of total revenue during the  period in comparison to revenue from sales the largest customer accounted for  to  of revenue during the same period as a consequence of current operations about onethird each of revenue and cost and expenses are denominated in swedish krona currency the remaining twothirds denominated in united states dollars this presents an element risk to the business based on unpredictable fluctuations in currency exchange rates intellectual propertyedit the companys protein arelated offerings are supported by proprietary technology trade secrets and patent filings one patent was granted in april  and has been extended so that it remains in effect until  patents are pending on elements of the opus chromatography product line and enabling technology has been licensed from bioflash partners repligen retains an exclusive license to intellectual property owned by the university of michigan in relation to the orencia product divested to bristolmyers squibb facilitiesedit repligens company headquarters are housed together with its manufacturing facility in waltham massachusetts repligen maintains manufacturing facilities in waltham massachusetts and lund sweden growth factor products and the native form of protein a are manufactured in sweden recombinant forms of protein a are manufactured in both the united states and sweden assembly of the opus chromatography product line is done in the united states the lease on the main waltham facility extends through  a second smaller waltham facility was leased through the end of  and is now rented on a monthly basis in lund four buildings are under lease three expiring in mid and the fourth extending to late  corporate history and governanceedit alexander rich was a cofounder of repligen in  at the age of  dr rich is chairman emeritusof repligens board of directors dr rich had been a member of the board since  paul schimmel is also a cofounder of repligen in  at the age of  he is the ernest and jean hahn professor at the skaggs institute for chemical biology at the scripps research institute he used to be the john d and catherine t macarthur professor of biochemistry and biophysics in the department of biology at mit as of update the companys president and chief executive officer is walter c herlihy acquisitions and inlicensingedit in early  repligen licensed technology from bioflash which it subsequently incorporated into the opus line of prepackaged chromatography columns in  repligen acquired bioproduction assets from novozymes for  million which doubled the companys bioprocessing capabilities in december  the company acquired tangenx for  million divestments and outlicensingedit in  an agreement was struck to divest certain intellectual property rights to bristolmyers squibb around the drug orencia in exchange for ongoing royalty payments through the end of  at the end of  repligen outlicensed its spinal muscular atrophy program in particular the small molecule candidate drug rg to pfizer this divestment included licensing rights to two patents to pfizer at the start of  the company outlicensed its friedreichs ataxia program including a library of histone deacetylase inhibitor compounds to biomarin pharmaceutical for us and future milestone and royalty payments terminations and mothballingedit development of an imaging agent designated rg based on a synthetic human hormone was halted in  following a request by the usfda for additional safety and efficacy data beyond that provided in a new drug application nda submission a marketing authorization application had been submitted in parallel to the ema financial historyedit financials from  k     revenue     operating income     net income     total assets     total equity     products and servicesedit repligen is a major supplier of protein a both native and recombinant forms to the pharmaceutical industry in  protein a accounted for the majority of the companys product sales the company also provides growth factors to increase the productivity of cellbased bioproduction multiple alternating tangential flow atf systems and a line opus of chromatography columns scaled to manufacture of product for testing in clinical trials the opus product line contains a range of column sizes the size and composition of which are dependent upon customer requirements thus the full name of open platform user specified the smaller sizes of columns depend upon proprietary technology licensed from bioflash partners while the larger sizes are based on repligendeveloped proprietary technology notesedit  as of  the companys logo image can be found at httpwwwrepligencomsitesallthemesrepligenimageslogocorporategif   a b c d repligen  k  p   nasdaq rgen  a b c d e repligen  k  p   a b c d e f repligen  k  p   a b repligen  k  p   a b c d e repligen  k  p   a b c repligen  k  p   a b c repligen  k  p   repligen  k  p   b us  b  nucleic acids encoding recombinant protein a  us   methods of treating autoimmune disease via ctlaig  a b repligen  k  p   a b repligen  k  p   a b motley fool   forbes   httpwwwgenengnewscomgennewshighlightsrepligenacquirestangenxform  us   diaminoquinazolines for spinal muscular atrophy  us   diaminoquinazolines for spinal muscular atrophy  gen eng biotechnol news   repligen  k  p   values are presented in thousands of us dollars    million negative values appear in parentheses referencesedit forbes  alexander rich profiles forbes archived from the original on  march  retrieved  march   gen eng biotechnol news february   biomarin nabs repligens hdaci compound library news discovery  development gen eng biotechnol news paper   p   international new york times  repligen corporation business day international new york times company information archived from the original on  march  retrieved  march   motley fool  repligen corp key executives rgen the motley fool archived from the original on  march  retrieved  march   repligen corporation form k  sec documents form k repligen  commission file number  retrieved  march   street insider  september  repligen rgen replaces board member alex rich with alfred goldberg street insider archived from the original on  march  retrieved  march   retrieved from httpsenwikipediaorgwindexphptitlerepligenoldid categories manufacturing support companiescompanies based in massachusettscompanies listed on nasdaq establishments in massachusettshidden categories articles containing potentially dated statements from february all articles containing potentially dated statementsarticles containing potentially dated statements from  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view repligen  wikipedia repligen from wikipedia the free encyclopedia jump to navigation search repligen corporation type public company traded as nasdaq rgen sp  component industry pharmaceutical industry founded  founder alexander rich and paul schimmel headquarters waltham massachusetts united states key people walter c herlihy president ceo products materials used in the manufacture of biological drugs revenue us million operating income us million total assets us million total equity us million number of employees   website wwwrepligencom repligen repligen in the companys logo is an american company devoted to the development and production of materials used in the manufacture of biological drugs the company is based in waltham massachusetts and incorporated in delaware in  a public company repligen is listed on the nasdaq exchange under the symbol rgen as of february update repligen employed  people about  of these based in sweden contents  business model  sales and revenue  intellectual property  facilities  corporate history and governance  acquisitions and inlicensing  divestments and outlicensing  terminations and mothballing  financial history  products and services  notes  references business modeledit prior to  repligen maintained dual capabilities in the development of pharmaceutical therapeutics drug discovery and development and the development of materials supporting biological drug manufacture bioprocessing business a decision was made in  to focus on the bioprocessing business and reduce research and development expenditures in the period of  to  the majority of sales by the company were concentrated in the single protein a product line sales and revenueedit repligen employs a direct sales model to users of its products in the united states with some sales through intermediaries in certain foreign markets more than  of sales have been to customers in the united states and sweden during the  period longterm supply agreements have been established with major customers of the protein a products agreements which expire between  and  barring renegotiation as a result of royaltygenerating outlicensing royalty revenue from bristolmyers squibb has been in the  to  range as a proportion of total revenue during the  period in comparison to revenue from sales the largest customer accounted for  to  of revenue during the same period as a consequence of current operations about onethird each of revenue and cost and expenses are denominated in swedish krona currency the remaining twothirds denominated in united states dollars this presents an element risk to the business based on unpredictable fluctuations in currency exchange rates intellectual propertyedit the companys protein arelated offerings are supported by proprietary technology trade secrets and patent filings one patent was granted in april  and has been extended so that it remains in effect until  patents are pending on elements of the opus chromatography product line and enabling technology has been licensed from bioflash partners repligen retains an exclusive license to intellectual property owned by the university of michigan in relation to the orencia product divested to bristolmyers squibb facilitiesedit repligens company headquarters are housed together with its manufacturing facility in waltham massachusetts repligen maintains manufacturing facilities in waltham massachusetts and lund sweden growth factor products and the native form of protein a are manufactured in sweden recombinant forms of protein a are manufactured in both the united states and sweden assembly of the opus chromatography product line is done in the united states the lease on the main waltham facility extends through  a second smaller waltham facility was leased through the end of  and is now rented on a monthly basis in lund four buildings are under lease three expiring in mid and the fourth extending to late  corporate history and governanceedit alexander rich was a cofounder of repligen in  at the age of  dr rich is chairman emeritusof repligens board of directors dr rich had been a member of the board since  paul schimmel is also a cofounder of repligen in  at the age of  he is the ernest and jean hahn professor at the skaggs institute for chemical biology at the scripps research institute he used to be the john d and catherine t macarthur professor of biochemistry and biophysics in the department of biology at mit as of update the companys president and chief executive officer is walter c herlihy acquisitions and inlicensingedit in early  repligen licensed technology from bioflash which it subsequently incorporated into the opus line of prepackaged chromatography columns in  repligen acquired bioproduction assets from novozymes for  million which doubled the companys bioprocessing capabilities in december  the company acquired tangenx for  million divestments and outlicensingedit in  an agreement was struck to divest certain intellectual property rights to bristolmyers squibb around the drug orencia in exchange for ongoing royalty payments through the end of  at the end of  repligen outlicensed its spinal muscular atrophy program in particular the small molecule candidate drug rg to pfizer this divestment included licensing rights to two patents to pfizer at the start of  the company outlicensed its friedreichs ataxia program including a library of histone deacetylase inhibitor compounds to biomarin pharmaceutical for us and future milestone and royalty payments terminations and mothballingedit development of an imaging agent designated rg based on a synthetic human hormone was halted in  following a request by the usfda for additional safety and efficacy data beyond that provided in a new drug application nda submission a marketing authorization application had been submitted in parallel to the ema financial historyedit financials from  k     revenue     operating income     net income     total assets     total equity     products and servicesedit repligen is a major supplier of protein a both native and recombinant forms to the pharmaceutical industry in  protein a accounted for the majority of the companys product sales the company also provides growth factors to increase the productivity of cellbased bioproduction multiple alternating tangential flow atf systems and a line opus of chromatography columns scaled to manufacture of product for testing in clinical trials the opus product line contains a range of column sizes the size and composition of which are dependent upon customer requirements thus the full name of open platform user specified the smaller sizes of columns depend upon proprietary technology licensed from bioflash partners while the larger sizes are based on repligendeveloped proprietary technology notesedit  as of  the companys logo image can be found at httpwwwrepligencomsitesallthemesrepligenimageslogocorporategif   a b c d repligen  k  p   nasdaq rgen  a b c d e repligen  k  p   a b c d e f repligen  k  p   a b repligen  k  p   a b c d e repligen  k  p   a b c repligen  k  p   a b c repligen  k  p   repligen  k  p   b us  b  nucleic acids encoding recombinant protein a  us   methods of treating autoimmune disease via ctlaig  a b repligen  k  p   a b repligen  k  p   a b motley fool   forbes   httpwwwgenengnewscomgennewshighlightsrepligenacquirestangenxform  us   diaminoquinazolines for spinal muscular atrophy  us   diaminoquinazolines for spinal muscular atrophy  gen eng biotechnol news   repligen  k  p   values are presented in thousands of us dollars    million negative values appear in parentheses referencesedit forbes  alexander rich profiles forbes archived from the original on  march  retrieved  march   gen eng biotechnol news february   biomarin nabs repligens hdaci compound library news discovery  development gen eng biotechnol news paper   p   international new york times  repligen corporation business day international new york times company information archived from the original on  march  retrieved  march   motley fool  repligen corp key executives rgen the motley fool archived from the original on  march  retrieved  march   repligen corporation form k  sec documents form k repligen  commission file number  retrieved  march   street insider  september  repligen rgen replaces board member alex rich with alfred goldberg street insider archived from the original on  march  retrieved  march   retrieved from httpsenwikipediaorgwindexphptitlerepligenoldid categories manufacturing support companiescompanies based in massachusettscompanies listed on nasdaq establishments in massachusettshidden categories articles containing potentially dated statements from february all articles containing potentially dated statementsarticles containing potentially dated statements from  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view repligen  wikipedia repligen from wikipedia the free encyclopedia jump to navigation search repligen corporation type public company traded as nasdaq rgen sp  component industry pharmaceutical industry founded  founder alexander rich and paul schimmel headquarters waltham massachusetts united states key people walter c herlihy president ceo products materials used in the manufacture of biological drugs revenue us million operating income us million total assets us million total equity us million number of employees   website wwwrepligencom repligen repligen in the companys logo is an american company devoted to the development and production of materials used in the manufacture of biological drugs the company is based in waltham massachusetts and incorporated in delaware in  a public company repligen is listed on the nasdaq exchange under the symbol rgen as of february update repligen employed  people about  of these based in sweden contents  business model  sales and revenue  intellectual property  facilities  corporate history and governance  acquisitions and inlicensing  divestments and outlicensing  terminations and mothballing  financial history  products and services  notes  references business modeledit prior to  repligen maintained dual capabilities in the development of pharmaceutical therapeutics drug discovery and development and the development of materials supporting biological drug manufacture bioprocessing business a decision was made in  to focus on the bioprocessing business and reduce research and development expenditures in the period of  to  the majority of sales by the company were concentrated in the single protein a product line sales and revenueedit repligen employs a direct sales model to users of its products in the united states with some sales through intermediaries in certain foreign markets more than  of sales have been to customers in the united states and sweden during the  period longterm supply agreements have been established with major customers of the protein a products agreements which expire between  and  barring renegotiation as a result of royaltygenerating outlicensing royalty revenue from bristolmyers squibb has been in the  to  range as a proportion of total revenue during the  period in comparison to revenue from sales the largest customer accounted for  to  of revenue during the same period as a consequence of current operations about onethird each of revenue and cost and expenses are denominated in swedish krona currency the remaining twothirds denominated in united states dollars this presents an element risk to the business based on unpredictable fluctuations in currency exchange rates intellectual propertyedit the companys protein arelated offerings are supported by proprietary technology trade secrets and patent filings one patent was granted in april  and has been extended so that it remains in effect until  patents are pending on elements of the opus chromatography product line and enabling technology has been licensed from bioflash partners repligen retains an exclusive license to intellectual property owned by the university of michigan in relation to the orencia product divested to bristolmyers squibb facilitiesedit repligens company headquarters are housed together with its manufacturing facility in waltham massachusetts repligen maintains manufacturing facilities in waltham massachusetts and lund sweden growth factor products and the native form of protein a are manufactured in sweden recombinant forms of protein a are manufactured in both the united states and sweden assembly of the opus chromatography product line is done in the united states the lease on the main waltham facility extends through  a second smaller waltham facility was leased through the end of  and is now rented on a monthly basis in lund four buildings are under lease three expiring in mid and the fourth extending to late  corporate history and governanceedit alexander rich was a cofounder of repligen in  at the age of  dr rich is chairman emeritusof repligens board of directors dr rich had been a member of the board since  paul schimmel is also a cofounder of repligen in  at the age of  he is the ernest and jean hahn professor at the skaggs institute for chemical biology at the scripps research institute he used to be the john d and catherine t macarthur professor of biochemistry and biophysics in the department of biology at mit as of update the companys president and chief executive officer is walter c herlihy acquisitions and inlicensingedit in early  repligen licensed technology from bioflash which it subsequently incorporated into the opus line of prepackaged chromatography columns in  repligen acquired bioproduction assets from novozymes for  million which doubled the companys bioprocessing capabilities in december  the company acquired tangenx for  million divestments and outlicensingedit in  an agreement was struck to divest certain intellectual property rights to bristolmyers squibb around the drug orencia in exchange for ongoing royalty payments through the end of  at the end of  repligen outlicensed its spinal muscular atrophy program in particular the small molecule candidate drug rg to pfizer this divestment included licensing rights to two patents to pfizer at the start of  the company outlicensed its friedreichs ataxia program including a library of histone deacetylase inhibitor compounds to biomarin pharmaceutical for us and future milestone and royalty payments terminations and mothballingedit development of an imaging agent designated rg based on a synthetic human hormone was halted in  following a request by the usfda for additional safety and efficacy data beyond that provided in a new drug application nda submission a marketing authorization application had been submitted in parallel to the ema financial historyedit financials from  k     revenue     operating income     net income     total assets     total equity     products and servicesedit repligen is a major supplier of protein a both native and recombinant forms to the pharmaceutical industry in  protein a accounted for the majority of the companys product sales the company also provides growth factors to increase the productivity of cellbased bioproduction multiple alternating tangential flow atf systems and a line opus of chromatography columns scaled to manufacture of product for testing in clinical trials the opus product line contains a range of column sizes the size and composition of which are dependent upon customer requirements thus the full name of open platform user specified the smaller sizes of columns depend upon proprietary technology licensed from bioflash partners while the larger sizes are based on repligendeveloped proprietary technology notesedit  as of  the companys logo image can be found at httpwwwrepligencomsitesallthemesrepligenimageslogocorporategif   a b c d repligen  k  p   nasdaq rgen  a b c d e repligen  k  p   a b c d e f repligen  k  p   a b repligen  k  p   a b c d e repligen  k  p   a b c repligen  k  p   a b c repligen  k  p   repligen  k  p   b us  b  nucleic acids encoding recombinant protein a  us   methods of treating autoimmune disease via ctlaig  a b repligen  k  p   a b repligen  k  p   a b motley fool   forbes   httpwwwgenengnewscomgennewshighlightsrepligenacquirestangenxform  us   diaminoquinazolines for spinal muscular atrophy  us   diaminoquinazolines for spinal muscular atrophy  gen eng biotechnol news   repligen  k  p   values are presented in thousands of us dollars    million negative values appear in parentheses referencesedit forbes  alexander rich profiles forbes archived from the original on  march  retrieved  march   gen eng biotechnol news february   biomarin nabs repligens hdaci compound library news discovery  development gen eng biotechnol news paper   p   international new york times  repligen corporation business day international new york times company information archived from the original on  march  retrieved  march   motley fool  repligen corp key executives rgen the motley fool archived from the original on  march  retrieved  march   repligen corporation form k  sec documents form k repligen  commission file number  retrieved  march   street insider  september  repligen rgen replaces board member alex rich with alfred goldberg street insider archived from the original on  march  retrieved  march   retrieved from httpsenwikipediaorgwindexphptitlerepligenoldid categories manufacturing support companiescompanies based in massachusettscompanies listed on nasdaq establishments in massachusettshidden categories articles containing potentially dated statements from february all articles containing potentially dated statementsarticles containing potentially dated statements from  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view stocks index  markets index bulletin investor alert new york markets open in market snapshot analyst ratings stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest axl group upgraded to overweight from neutral at jp morgan astarbucks stock price target cut to  from  at jp morgan agoodyear tires stock dives after slashed profit outlook offsets inline earnings awatch out ‘kids’ are making the most money in this stock market astock market set to extend fresh tech rout as amazon disappoints gdp data ahead ashares of video game maker activision blizzard down more than  aintel earnings have message for amd and nvidia ‘bring it on’ aaarons shares up nearly  in friday premarket trading aamazon’s freespending ways hit earnings but don’t expect a shift to thrift aabbvie shares up  in premarket trade aabbvie still sees fullyear adj eps  to  aabbvie still sees fullyear eps  to  aabbvie q revenue  bln vs  bln factset consensus  bln aabbvie q adj eps  factset consensus  agoodyears stock plunges  premarket after q results aabbvie q eps  vs  cents agoodyear cuts  segment operating income outlook to  bln bln from  bln aget ready for the lessprofitable amazon that you used to know awells fargo charged customers for duplicate car insurance agoodyear q sales  bln vs  bln factset consensus  bln loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  repligen  wikipedia repligen from wikipedia the free encyclopedia jump to navigation search repligen corporation type public company traded as nasdaq rgen sp  component industry pharmaceutical industry founded  founder alexander rich and paul schimmel headquarters waltham massachusetts united states key people walter c herlihy president ceo products materials used in the manufacture of biological drugs revenue us million operating income us million total assets us million total equity us million number of employees   website wwwrepligencom repligen repligen in the companys logo is an american company devoted to the development and production of materials used in the manufacture of biological drugs the company is based in waltham massachusetts and incorporated in delaware in  a public company repligen is listed on the nasdaq exchange under the symbol rgen as of february update repligen employed  people about  of these based in sweden contents  business model  sales and revenue  intellectual property  facilities  corporate history and governance  acquisitions and inlicensing  divestments and outlicensing  terminations and mothballing  financial history  products and services  notes  references business modeledit prior to  repligen maintained dual capabilities in the development of pharmaceutical therapeutics drug discovery and development and the development of materials supporting biological drug manufacture bioprocessing business a decision was made in  to focus on the bioprocessing business and reduce research and development expenditures in the period of  to  the majority of sales by the company were concentrated in the single protein a product line sales and revenueedit repligen employs a direct sales model to users of its products in the united states with some sales through intermediaries in certain foreign markets more than  of sales have been to customers in the united states and sweden during the  period longterm supply agreements have been established with major customers of the protein a products agreements which expire between  and  barring renegotiation as a result of royaltygenerating outlicensing royalty revenue from bristolmyers squibb has been in the  to  range as a proportion of total revenue during the  period in comparison to revenue from sales the largest customer accounted for  to  of revenue during the same period as a consequence of current operations about onethird each of revenue and cost and expenses are denominated in swedish krona currency the remaining twothirds denominated in united states dollars this presents an element risk to the business based on unpredictable fluctuations in currency exchange rates intellectual propertyedit the companys protein arelated offerings are supported by proprietary technology trade secrets and patent filings one patent was granted in april  and has been extended so that it remains in effect until  patents are pending on elements of the opus chromatography product line and enabling technology has been licensed from bioflash partners repligen retains an exclusive license to intellectual property owned by the university of michigan in relation to the orencia product divested to bristolmyers squibb facilitiesedit repligens company headquarters are housed together with its manufacturing facility in waltham massachusetts repligen maintains manufacturing facilities in waltham massachusetts and lund sweden growth factor products and the native form of protein a are manufactured in sweden recombinant forms of protein a are manufactured in both the united states and sweden assembly of the opus chromatography product line is done in the united states the lease on the main waltham facility extends through  a second smaller waltham facility was leased through the end of  and is now rented on a monthly basis in lund four buildings are under lease three expiring in mid and the fourth extending to late  corporate history and governanceedit alexander rich was a cofounder of repligen in  at the age of  dr rich is chairman emeritusof repligens board of directors dr rich had been a member of the board since  paul schimmel is also a cofounder of repligen in  at the age of  he is the ernest and jean hahn professor at the skaggs institute for chemical biology at the scripps research institute he used to be the john d and catherine t macarthur professor of biochemistry and biophysics in the department of biology at mit as of update the companys president and chief executive officer is walter c herlihy acquisitions and inlicensingedit in early  repligen licensed technology from bioflash which it subsequently incorporated into the opus line of prepackaged chromatography columns in  repligen acquired bioproduction assets from novozymes for  million which doubled the companys bioprocessing capabilities in december  the company acquired tangenx for  million divestments and outlicensingedit in  an agreement was struck to divest certain intellectual property rights to bristolmyers squibb around the drug orencia in exchange for ongoing royalty payments through the end of  at the end of  repligen outlicensed its spinal muscular atrophy program in particular the small molecule candidate drug rg to pfizer this divestment included licensing rights to two patents to pfizer at the start of  the company outlicensed its friedreichs ataxia program including a library of histone deacetylase inhibitor compounds to biomarin pharmaceutical for us and future milestone and royalty payments terminations and mothballingedit development of an imaging agent designated rg based on a synthetic human hormone was halted in  following a request by the usfda for additional safety and efficacy data beyond that provided in a new drug application nda submission a marketing authorization application had been submitted in parallel to the ema financial historyedit financials from  k     revenue     operating income     net income     total assets     total equity     products and servicesedit repligen is a major supplier of protein a both native and recombinant forms to the pharmaceutical industry in  protein a accounted for the majority of the companys product sales the company also provides growth factors to increase the productivity of cellbased bioproduction multiple alternating tangential flow atf systems and a line opus of chromatography columns scaled to manufacture of product for testing in clinical trials the opus product line contains a range of column sizes the size and composition of which are dependent upon customer requirements thus the full name of open platform user specified the smaller sizes of columns depend upon proprietary technology licensed from bioflash partners while the larger sizes are based on repligendeveloped proprietary technology notesedit  as of  the companys logo image can be found at httpwwwrepligencomsitesallthemesrepligenimageslogocorporategif   a b c d repligen  k  p   nasdaq rgen  a b c d e repligen  k  p   a b c d e f repligen  k  p   a b repligen  k  p   a b c d e repligen  k  p   a b c repligen  k  p   a b c repligen  k  p   repligen  k  p   b us  b  nucleic acids encoding recombinant protein a  us   methods of treating autoimmune disease via ctlaig  a b repligen  k  p   a b repligen  k  p   a b motley fool   forbes   httpwwwgenengnewscomgennewshighlightsrepligenacquirestangenxform  us   diaminoquinazolines for spinal muscular atrophy  us   diaminoquinazolines for spinal muscular atrophy  gen eng biotechnol news   repligen  k  p   values are presented in thousands of us dollars    million negative values appear in parentheses referencesedit forbes  alexander rich profiles forbes archived from the original on  march  retrieved  march   gen eng biotechnol news february   biomarin nabs repligens hdaci compound library news discovery  development gen eng biotechnol news paper   p   international new york times  repligen corporation business day international new york times company information archived from the original on  march  retrieved  march   motley fool  repligen corp key executives rgen the motley fool archived from the original on  march  retrieved  march   repligen corporation form k  sec documents form k repligen  commission file number  retrieved  march   street insider  september  repligen rgen replaces board member alex rich with alfred goldberg street insider archived from the original on  march  retrieved  march   retrieved from httpsenwikipediaorgwindexphptitlerepligenoldid categories manufacturing support companiescompanies based in massachusettscompanies listed on nasdaq establishments in massachusettshidden categories articles containing potentially dated statements from february all articles containing potentially dated statementsarticles containing potentially dated statements from  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view data dumps    freebase api deprecated    google developers freebase api deprecated all products sign in send feedback hey there are you maybe looking for firebase instead data dumps the freebase api will be completely shutdown on aug   this page provides access to the last available data dump read more data dumps are a downloadable version of the data in freebase they constitute a snapshot of the data stored in freebase and the schema that structures it and are provided under the same ccby license the freebasewikidata mappings are provided under the cc license freebase triples freebase deleted triples freebasewikidata mappings license citing freebase triples this dataset contains every fact currently in freebase total triples  billion updated weekly data format ntriples rdf license ccby  gb gzip gb uncompressed download the rdf data is serialized using the ntriples format encoded as utf text and compressed with gzip rdf httprdffreebasecomnsgvjzynm httprdffreebasecomnsmeasurementunitdatedpercentagedate httpwwwworgxmlschemagyearmonth  httprdffreebasecomnsgvjzynm httprdffreebasecomnsmeasurementunitdatedpercentagesource httprdffreebasecomnsgxgfm  httprdffreebasecomnsgvjzynm httprdffreebasecomnstypeobjecttype httprdffreebasecomnsmeasurementunitdatedpercentage  httprdffreebasecomnsgvjzynm httprdffreebasecomnsmeasurementunitdatedpercentagerate   httprdffreebasecomnsgvjzynm httpwwwworgrdfsyntaxnstype httprdffreebasecomnsmeasurementunitdatedpercentage  if youre writing your own code to parse the rdf dumps its often more efficient to read directly from gzip file rather than extracting the data first and then processing the uncompressed data subject predicate object  note in freebase objects have mids that look like mrkqx in rdf those mids become mrkqx likewise freebase schema like commontopic are written as commontopic the subject is the id of a freebase object it can be a freebase mid ex mrkqx for topics and cvts or a humanreadable id ex commontopic for schema the predicate is always a humanreadable id for a freebase property or a property from a standard rdf vocabulary like rdfs freebase foreign key namespaces are also used as predicates to make it easier to look up keys by namespace the object field may contain a freebase mid for an object or a humanreadable id for schema from freebase or other rdf vocabularies it may also include literal values like strings booleans and numeric values topic descriptions often contain newlines in order to make each triple fit on one line we have escaped newlines with n freebase deleted triples we also provide a dump of triples that have been deleted from freebase over time this is a onetime dump through march  in the future we might consider providing periodic updates of recently deleted triples but at the moment we have no specific timeframe for doing so and are only providing this onetime dump the dump is distributed as a targz file gb compressed gb uncompressed it contains  deleted triples in  files there is no particular meaning to the individual files it is just easier to manipulate several smaller files than one huge file thanks to chun how tan and john giannandrea for making this data release possible total triples  million updated june   data format csv license ccby  gb gzip gb uncompressed download the data format is essentially csv with one important caveat the object field may contain any characters including commas as well as any other reasonable delimiters you could think of however all the other fields are guaranteed not to contain commas so the data can still be parsed unambiguously the columns in the dataset are defined as creationtimestamp unix epoch time in milliseconds creator deletiontimestamp unix epoch time in milliseconds deletor subject mid predicate mid object midliteral languagecode csv usermwclwikipediaenusermwclwikipediaenmrtypeobjectkeywikipediaenben usermwclmusicbrainzuserturtlewaxbotmnncpzmusicrecordingartistmvbfmen usermwclimagesusergardeningbotmwmcommonimagesizemklyen usermwclmusicbrainzusermbzpipelinemergebotmfvvltypeobjecttypecommontopicen usermwclimagesusergardeningbotmxsczcommonlicensedobjectlicensemxben usercontentadministratorusergardeningbotmgkbytypeobjecttypetypecontenten usermwclimagesusergardeningbotmhcommontopicimagemcsen usermwclchefmozuserdeletebotmzcztypeobjectnamela casa rosa mexican restauranten freebasewikidata mappings the data has been created based on the wikidatadump of october   and contains only those links that have at least two common wikipedialinks and not a single disagreeing wikipedialink furthermore the lines are sorted by the number of common wikipedialinks although in turtle this does not really matter total triples m updated october   data format ntriples rdf license cc  mb gzip mb uncompressed download the rdf data is serialized using the ntriples format encoded as utf text and compressed with gzip rdf httprdffreebasecomnsmj httpwwwworgowlsameas httpwwwwikidataorgentityq  httprdffreebasecomnsmnrg httpwwwworgowlsameas httpwwwwikidataorgentityq  httprdffreebasecomnsmjgd httpwwwworgowlsameas httpwwwwikidataorgentityq  httprdffreebasecomnsmd httpwwwworgowlsameas httpwwwwikidataorgentityq  httprdffreebasecomnsmgd httpwwwworgowlsameas httpwwwwikidataorgentityq  license freebase data dumps are provided free of charge for any purpose with regular updates by google they are distributed like freebase itself under the creative commons attribution aka ccby and use is subject to the terms of service the freebasewikidata id mappings are provided under cc and can be used without restrictions citing if youd like to cite these data dumps in a publication you may use google freebase data dumps httpsdevelopersgooglecomfreebasedata month day year or as bibtex bibtex misc date name shares transaction value  jon k snodgres cfo    derivativenonderivative trans at  per share   karen a dawes director    award at  per share   glenn l cooper director    award at  per share   thomas f ryan director    award at  per share   john g cox director    award at  per share   nicolas m barthelemy director    award at  per share   glenn p muir director    award at  per share   tony j hunt chief executive officer    derivativenonderivative trans at  per share   thomas f ryan director    gift at  per share   thomas f ryan director    gift at  per share   karen a dawes director    disposition at  per share   karen a dawes director    derivativenonderivative trans at  per share   howard benjamin vp business development    derivativenonderivative trans at  per share   howard benjamin vp business development    derivativenonderivative trans at  per share   thomas f ryan director    derivativenonderivative trans at  per share   howard benjamin vp business development    disposition at  per share   howard benjamin vp business development    disposition at  per share   thomas f ryan director    disposition at  per share   jon k snodgres cfo    derivativenonderivative trans at  per share   jon k snodgres cfo    disposition at  per share   tony j hunt chief executive officer    derivativenonderivative trans at  per share   howard benjamin vp business development    derivativenonderivative trans at  per share   jon k snodgres cfo    derivativenonderivative trans at  per share   tony j hunt chief executive officer    award at  per share   howard benjamin vp business development    award at  per share   jon k snodgres cfo    award at  per share   james r rusche senior vice president    gift at  per share  newslatestcompanyusrgen marketwatch news on rgen repligen stock fair value estimate raised to  from  at janney  am june    tomi kilgore repligen to buy filtration company spectrum for  million in cash and stock  am june    tomi kilgore repligen agrees to buy spectrum in a cashandstock deal valued at  mln  am june    tomi kilgore repligens stock halted for news pending  am june    tomi kilgore repligens stock was inactive premarket prior to trading halt  am june    tomi kilgore market sends a message cash is king  pm june    the trading deck cash aint trash as the stock market behaves bearishly  pm may    the trading deck nasdaq still has many opportunities for speculators  pm april    the trading deck bull trend absorbs soft secondquarter start  am april    michael ashbaugh these are the most profitable nasdaq biotech companies  pm march    philip van doorn here are the bestperforming stocks so far in   pm jan    philip van doorn speculators live by the sword die by the sword  pm july    the trading deck repligen corp up  in premarket  am jan    steve gelsi friday’s biggest gaining and declining stocks  pm june    marketwatch repligen fda wants more trials for secretin drug  pm june    marketwatchcom fda gives repligens secreflo priority status  am feb    marketwatchcom repligen receives fasttrack designation from fda  am june    marketwatchcom sanofi regeneron report progress with cancer drug  am june    robert daniel monday’s biggest gaining and declining stocks  pm march    christopher hinton repligen paces downturn in biotech stocks  pm march    wallace witkowski loading more headlines newsnonmarketwatchcompanyusrgen other news on rgen benin management corp buys prudential financial inc united parcel service inc chevron corp   pm july    gurufocuscom top ranked momentum stocks to buy for july rd  am july    zackscom repligen spectrum purchase makes sense but leaves shares more than fully valued  pm june    seeking alpha repligen to merge with spectrum in m deal  am june    seeking alpha repligen corporation rgen bank of america merrill lynch  health care conference  slideshow  pm may    seeking alpha repligens rgen ceo tony hunt on q  results  earnings call transcript  pm may    seeking alpha trade of the day repligen nasdaqrgen  am may    investorplacecom q repligen corp  pm may    edgar online  edg  q k solaris asset management llc buys ishares core sp midcap berkshire hathaway inc   pm may    gurufocuscom notable earnings before thursday’s open  pm may    seeking alpha premarket analyst action  healthcare  am april    seeking alpha repligens rgen ceo tony hunt on q  results  earnings call transcript  pm feb    seeking alpha repligen revenues up  nongaap eps up  in fy updates guidance  am feb    seeking alpha  a record year  am jan    seeking alpha repligen corporation rgen presents at th annual jp morgan healthcare conference  am jan    seeking alpha the zacks analyst blog highlights sucampo pharmaceuticals dr reddys laboratories biomarin pharmaceutical and repligen  am jan    zackscom  overlooked drug stocks to watch out for in   am jan    zackscom  biotechnology stocks to sell now  am dec    investorplacecom repligen buys tangenx technology expected to be accretive to eps in   am dec    seeking alpha hottest manufacturing stocks now – rdus atra rare cmco  pm nov    investorplacecom loading more headlines at a glance repligen corp  seyon street building  suite  waltham massachusetts  phone   industry biotechnology sector health carelife sciences fiscal yearend  view sec filings revenue m net income m  sales growth  employees  annual report for rgen newspressreleasecompanyusrgen press releases on rgen repligen to report second quarter  financial results  am july    globenewswire repligen corporation prices public offering of shares of common stock  pm june    globenewswire repligen corporation announces proposed public offering of shares of common stock  pm june    globenewswire corporate news blog  repligen corp and spectrum merge to form leader in filtration for bioprocessing industry  am june    accesswire repligen corporation and spectrum inc to join forces  am june    globenewswire repligen to present at jefferies  global annual healthcare conference  am may    globenewswire repligen to participate in th annual craighallum institutional investor conference  am may    globenewswire repligen to present at bank of america merrill lynch  healthcare conference  pm may    globenewswire repligen reports first quarter  financial results  am may    globenewswire investor network repligen corporation to host earnings call  am may    accesswire repligen to report first quarter  financial results  am april    globenewswire repligen reports fourth quarter  financial results provides guidance for   am feb    globenewswire repligen to report fourth quarter and full year  financial results provides financial guidance for   pm feb    globenewswire repligen to present at th annual jp morgan healthcare conference  am jan    globenewswire blog coverage repligen acquires maker of tangential flow filtration cassettes  am dec    accesswire update  repligen acquires tangenx technology corporation  am dec    globenewswire repligen acquires tangenx technology corporation  am dec    globenewswire prepacked chromatography columns market  global industry analysis size share growth trends and forecast     pm nov    pr newswire  prf repligen to participate in stephens inc fall investment conference   pm nov    globenewswire repligen to report third quarter  financial results  am oct    globenewswire loading more headlines trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite tlt quoteszigmancomposite jnug x powered by log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest axl group upgraded to overweight from neutral at jp morgan astarbucks stock price target cut to  from  at jp morgan agoodyear tires stock dives after slashed profit outlook offsets inline earnings awatch out ‘kids’ are making the most money in this stock market astock market set to extend fresh tech rout as amazon disappoints gdp data ahead ashares of video game maker activision blizzard down more than  aintel earnings have message for amd and nvidia ‘bring it on’ aaarons shares up nearly  in friday premarket trading aamazon’s freespending ways hit earnings but don’t expect a shift to thrift aabbvie shares up  in premarket trade aabbvie still sees fullyear adj eps  to  aabbvie still sees fullyear eps  to  aabbvie q revenue  bln vs  bln factset consensus  bln aabbvie q adj eps  factset consensus  agoodyears stock plunges  premarket after q results aabbvie q eps  vs  cents agoodyear cuts  segment operating income outlook to  bln bln from  bln aget ready for the lessprofitable amazon that you used to know awells fargo charged customers for duplicate car insurance agoodyear q sales  bln vs  bln factset consensus  bln loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  rgen  stock quote for repligen corp  msn money msn back to msn home money web search sign in change language  content américa latina español argentina español australia english belgië nederlands belgique français brasil português canada english canada français chile español colombia español danmark dansk deutschland deutsch españa español france français india english indonesia bahasa indonesia ireland english italia italiano malaysia english méxico español nederland nederlands new zealand english norge norsk bokmål österreich deutsch perú español philippines english polska polski portugal português schweiz deutsch singapore english south africa english suisse français suomi suomi sverige svenska türkiye türkçe united arab emirates english united kingdom english united states english united states español venezuela español việt nam tiếng việt ελλάδα ελληνικά россия pусский ישראל עברית‏ الإمارات العربية المتحدة العربية‏ المملكة العربية السعودية العربية‏ مصر العربية‏ ไทย ไทย 한국 한국어  简体  繁體  語  繁體 switch to latino español feedback help adchoices repligen corp nasdaq rgen us markets open in hr  min adchoices  ▼   after hours     july    pm edt delayed  minutes nasdaq currency in usd save summary financials analysis options ownership company history related open  previous close  volume avg k k days range  wk range  market cap b dividend rate  yield  beta  shares outstanding m pe ratio eps   recent news repligen spectrum purchase makes sense but leaves shares more than fully valued seeking alpha  days ago bipolar disorder market size to grow exponentially during the assessment period  openprcom  hr ago facts about substance abuse drugs and alcohol  common side effects of medications for mental disorders include all of the following except channel buzz  hrs ago eps for repligen rgen expected at   bullish analysts covering ryland group ryl the bibey post  hrs ago repligen to report second quarter  financial results it business net  hrs ago cyrus biotechnology inc company profile bioportfoliocom  day ago perfusion systems market  share  forecast  –  medgadget  day ago repligen rgen analysts see  eps kdi capital partners decreased cvs health cvs holding the bibey post  day ago prepacked column market indepth analysis of trends and potentiality through  sbwirecom  days ago research report explores the top company profiles of perfusion systems market to  whatech  days ago repligen corporation rgen expected to post q  earnings of  per share themarketsdailycom  days ago repligen corporation rgen coverage initiated by analysts at william blair themarketsdailycom  days ago first quadrant lp ca has  million stake in wells fargo  company joshnaijablogcom  days ago wells fargo  company wfc shares bought by arcadia investment management corp mi giftedvizcom  days ago wells fargo  company wfc shares sold by northpointe capital llc badhubnet  days ago apg asset management nv raises its investment in wells fargo  company leisuretravelaidcom  days ago revenue estimates analysis wells fargo  company theaviationweeknet  days ago berenberg may have just lost faith in wells fargo nysewfc wp super fanboy  days ago adchoices adchoices adchoices markets dow dow ▲    last updated time   pm edt markets nasdaq nasdaq ▼    ftse  ftse  ▼    nyse composite nyse composite ▼    adchoices feedback send feedback provide feedback report a problem we appreciate your input select a category im having problems with top destinations im having issues searching im having problems with featured apps i see an error in the content other how we can improve please give an overall site rating submit close privacy statement help help  support facebook autocomplete demo post a rating  month price target   home trending sign up log in analyst ranking   name measured ratings sucess rate avg return  mizuho      credit suisse      jefferies      cantor fitzgerald      bank of america merrill lynch      jmp securities      goldman sachs      raymond james      fbr capital markets      william blair     flashratings  contact us facebook autocomplete demo post a rating  month price target   trending sign up log in contact flashratings your emotional state excited confused worried upset panicked angry repligen mantibodynews  twitter skip to content home home home current page moments moments moments current page search query search twitter saved searches remove in this conversation verified accountprotected tweets  suggested users verified accountprotected tweets  verified accountprotected tweets  language english bahasa indonesia bahasa melayu català čeština dansk deutsch english uk español filipino français hrvatski italiano magyar nederlands norsk polski português română slovenčina suomi svenska tiếng việt türkçe ελληνικά български език русский српски українська мова עִבְרִית العربية فارسی मराठी हिन्दी বাংলা ગુજરાતી தமிழ் ಕನ್ನಡ ภาษาไทย 한국어 語 简体 繁體 have an account log in have an account remember me · forgot password new to twitter sign up repligen mantibodynews tweets tweets current page  following following  followers followers    more unmute mantibodynews mute mantibodynews follow following unfollow blocked unblock pending cancel repligen mantibodynews nearly all therapeutic monoclonal antibodies mabs on the market or in development are produced using bioprocessing products manufactured by repligen waltham ma and lund sweden repligencom joined september   photos and videos photos and videos tweets tweets tweets current page tweets  replies media you blocked mantibodynews are you sure you want to view these tweets viewing tweets wont unblock mantibodynews yes view profile close repligen followed repligen‏ mantibodynews jul  more copy link to tweet embed tweet us fda gives thumbs up to avastin and herceptin biosimilars httpwwwbiopharmareportercommarketsregulationsusfdagivesthumbsuptoavastinandherceptinbiosimilarsutmsourceaddthistwitterutmmediumtwitterutmcampaignsocialmediawxerelhkeutwitter … via biopharmareport  replies  retweets  likes reply retweet retweeted like liked thanks twitter will use this to make your timeline better undo repligen‏ mantibodynews jul  more copy link to tweet embed tweet lonza expands in asia l singleuse in singapore regenerative meds in japan httpwwwbiopharmareportercomupstreamprocessinglonzaaddsdisposableandcellgenetherapycapabilitiesinasiautmsourceaddthistwitterutmmediumtwitterutmcampaignsocialmediawxerfwqohictwitter … via biopharmareport  replies  retweets  likes reply retweet retweeted like liked thanks twitter will use this to make your timeline better undo repligen‏ mantibodynews jul  more copy link to tweet embed tweet boehringer ingelheim expands in california adds  jobs httpwwwbiopharmareportercommarketsregulationsboehringeringelheimexpandsincaliforniaaddsjobsutmsourceaddthistwitterutmmediumtwitterutmcampaignsocialmediawxeqpcdqistwitter … via biopharmareport  replies  retweets  likes reply retweet retweeted like liked thanks twitter will use this to make your timeline better undo repligen‏ mantibodynews jul  more copy link to tweet embed tweet samsung biologics reducing cogs could double mammalian cmo use to  httpwwwbiopharmareportercommarketsregulationssamsungbiologicslookstodrivebigpharmatooutsourcebioproductionutmsourceaddthistwitterutmmediumtwitterutmcampaignsocialmediawxeqqkxtuitwitter … via biopharmareport  replies  retweets  likes reply retweet retweeted like liked thanks twitter will use this to make your timeline better undo repligen‏ mantibodynews jul  more copy link to tweet embed tweet boehringer to spend m to upgrade plant to boost production httpwwwfiercepharmacommanufacturingboehringertospendmtoupgradefremontcaplanttoboostproduction …  replies  retweets  likes reply retweet retweeted like liked thanks twitter will use this to make your timeline better undo repligen‏ mantibodynews jul  more copy link to tweet embed tweet lilly’s catchup act in psoriasis is working but now it has to catch up in cancer httpwwwfiercepharmacomfinancialslillyscatchupactpsoriasisworkingbutnowithastocatchupcancer …  replies  retweets  likes reply retweet retweeted like liked thanks twitter will use this to make your timeline better undo repligen‏ mantibodynews jul  more copy link to tweet embed tweet keytruda fail small beans for merck bigger riddle for immunooncology scorekeepers httpwwwfiercepharmacompharmakeytrudafailsmallbeansformerckbiggerriddleforimmunooncologyscorecard …  replies  retweets  likes reply retweet retweeted like liked thanks twitter will use this to make your timeline better undo repligen‏ mantibodynews jul  more copy link to tweet embed tweet targeting a b brand samsung and merck launch remicade biosim at  discount httpwwwfiercepharmacompharmasamsungmercklaunchremicadebiosimatdiscount …  replies  retweets  likes reply retweet retweeted like liked thanks twitter will use this to make your timeline better undo repligen‏ mantibodynews jul  more copy link to tweet embed tweet lilly firms up adimab rd alliance bringing its ab platform inhouse httpwwwfiercebiotechcombiotechlillyfirmsupadimabrdalliancebringingitsabplatformhouse …  replies  retweets  likes reply retweet retweeted like liked thanks twitter will use this to make your timeline better undo repligen‏ mantibodynews jul  more copy link to tweet embed tweet jj gets a quick fda ok for its blockbuster psoriasis contender guselkumab  httpsendptscomthankyou   replies  retweets  likes reply retweet retweeted like liked thanks twitter will use this to make your timeline better undo repligen‏ mantibodynews jul  more copy link to tweet embed tweet fda grants full approval to amgens blincyto for allhttpsbnewsrxymy   replies  retweets  likes reply retweet retweeted like liked thanks twitter will use this to make your timeline better undo repligen‏ mantibodynews jul  more copy link to tweet embed tweet emicizumab trial finds  reduction in hemophilia bleeding episodeshttpsbnewsrxydi   replies  retweets  likes reply retweet retweeted like liked thanks twitter will use this to make your timeline better undo repligen‏ mantibodynews jul  more copy link to tweet embed tweet sun shines on cmo samsung biologics to make its psoriasis mab candidatehttpwwwbiopharmareportercomupstreamprocessingsunshinesonsamsungbiologicstomakeitspsoriasismabcandidatewvvspogrowtwitter …  replies  retweets  likes reply retweet retweeted like liked thanks twitter will use this to make your timeline better undo repligen‏ mantibodynews jun  more copy link to tweet embed tweet little alder bags positive phiii migraine data but giant rivals are racing ahead in a crowded field httpsendptscomlittlealderbagspositivephiiimigrainedatabutgiantrivalsareracingaheadinacrowdedfield …  replies  retweets  likes reply retweet retweeted like liked thanks twitter will use this to make your timeline better undo repligen‏ mantibodynews jun  more copy link to tweet embed tweet humira facing building pressure in eu as samsung biogen get nod for biosimilar httpwwwfiercepharmacompharmahumirafacingnewpressureeuassamsungbiogengetnodforbiosimilar …  replies  retweets  likes reply retweet retweeted like liked thanks twitter will use this to make your timeline better undo repligen‏ mantibodynews jun  more copy link to tweet embed tweet updated novartis’ big phiii for canakinumab scores a surprise win helping heart attack patients httpsendptscomnovartisbigcardiophiiiforcanakinumabscoresasurprisewinhelpingheartattackpatients …  replies  retweets  likes reply retweet retweeted like liked thanks twitter will use this to make your timeline better undo repligen‏ mantibodynews jun  more copy link to tweet embed tweet seattle genetics stops all trials of a blood cancer drug vadastuximab after patient deaths httpwwwfiercebiotechcombiotechseattlegeneticsstopsalltrialsabloodcancerdrugafterpatientdeaths …  replies  retweet  likes reply retweet  retweeted  like liked thanks twitter will use this to make your timeline better undo repligen‏ mantibodynews jun  more copy link to tweet embed tweet amgen bioprocess intensification and integration key for nextgeneration manufacturing httpwwwbiopharmareportercomdownstreamprocessingamgenbeyondsingaporebioprocessintensificationandintegrationutmsourceaddthistwitterutmmediumtwitterutmcampaignsocialmediawufekcpqgtwitter … via biopharmareport  replies  retweets  likes reply retweet retweeted like liked thanks twitter will use this to make your timeline better undo repligen‏ mantibodynews jun  more copy link to tweet embed tweet jj confident of retaining remicade rewards as biosimilar clouds gather httpwwwbiopharmareportercommarketsregulationsjanssenatleastmoreyearsofmultibilliondollarremicadesalesutmsourceaddthistwitterutmmediumtwitterutmcampaignsocialmediawufexryolqtwitter … via biopharmareport  replies  retweets  likes reply retweet retweeted like liked thanks twitter will use this to make your timeline better undo repligen‏ mantibodynews jun  more copy link to tweet embed tweet merck halts enrollment on two phiii keytruda combo studies as outside monitors flag a worrying rate of deaths httpsendptscommerckhaltsenrollmentontwophiiikeytrudastudiesasoutsidemonitorsflagaworryingrateofdeaths …  replies  retweets  likes reply retweet retweeted like liked thanks twitter will use this to make your timeline better undo mantibodynews hasnt tweeted yet back to top ↑ loading seems to be taking a while twitter may be over capacity or experiencing a momentary hiccup try again or visit twitter status for more information new to twitter sign up now to get your own personalized timeline sign up you may also like · refresh false   twitter about help center terms privacy policy cookies ads info close choose a trend location dismiss close previous next close go to a persons profile saved searches remove in this conversation verified accountprotected tweets  suggested users verified accountprotected tweets  verified accountprotected tweets  close promote this tweet close block cancel block add a location to your tweets when you tweet with a location twitter stores that location you can switch location onoff before each tweet and always have the option to delete your location history learn more turn location on not now close share location results from send close your lists close create a new list list name description under  characters optional privacy public · anyone can follow this list private · only you can access this list save list close close copy link to tweet heres the url for this tweet copy it to easily share with friends close embed this tweet embed this video add this tweet to your website by copying the code below learn more add this video to your website by copying the code below learn more hmm there was a problem reaching the server try again include parent tweet include media by embedding twitter content in your website or app you are agreeing to the twitter developer agreement and developer policy preview close why youre seeing this ad close log in to twitter remember me · forgot password dont have an account sign up » close sign up for twitter not on twitter sign up tune into the things you care about and get updates as they happen sign up have an account log in » close twoway sending and receiving short codes country code for customers of united states  any canada  any united kingdom  vodafone orange  o brazil  nextel tim haiti  digicel voila ireland  vodafone o india  bharti airtel videocon reliance indonesia  axis  telkomsel indosat xl axiata italy  wind  vodafone » see sms short codes for other countries close confirmation close   close skip all welcome home this timeline is where you’ll spend most of your time getting instant updates about what matters to you tweets not working for you hover over the profile pic and click the following button to unfollow any account say a lot with a little when you see a tweet you love tap the heart — it lets the person who wrote it know you shared the love spread the word the fastest way to share someone else’s tweet with your followers is with a retweet tap the icon to send it instantly join the conversation add your thoughts about any tweet with a reply find a topic you’re passionate about and jump right in learn the latest get instant insight into what people are talking about now get more of what you love follow more accounts to get instant updates about topics you care about find whats happening see the latest conversations about any topic instantly never miss a moment catch up instantly on the best stories happening as they unfold back next next tweet from user corporategiftsnetworkcom  copyright all rights reserved the sponsored listings displayed above are served automatically by a third party neither the service provider nor the domain owner maintain any relationship with the advertisers in case of trademark issues please contact the domain owner directly contact information can be found in whois privacy policy history  repligen homeproductsapplicationsresourcescompanyabout usleadershipoperationscareershistorynewsroomcontactinvestors menu   items  sign in homeproductsupstream solutionsxcell atf systemcell culture supplementsdownstream solutionsopus prepacked columnstangenx tff cassettesprotein a affinity resinsprotein a ligandsanalyticselisa kitsdistributorsstoreapplicationsupstream applicationsperfusionn perfusionhigh density cell bankingmedia optimization  growth factorsdownstream applicationsprepacked columnsmulticolumn chromatographyconcentration and diafiltrationprocess intensificationcontinuous processingintegrated continuous processingresourceseventslibraryquality documentscompanyabout usleadershipoperationscareerscareer opportunitieshistorynewsroomcontactinvestorscorporate profilepress releasesinvestor presentations and eventsleadershipcorporate governancefinancial informationinteractive analyst centersec filingsannual reportsstock informationstock quoteinvestment calculatorownership profileanalyst coveragecontacts and alertsinvestor faq history founded in  by two pioneering scientists repligen is a leader today in protein a ligand manufacturing and is focused on becoming a trusted solutions provider for bioprocessing founders repligen was founded in  by two distinguished scientists who pioneered breakthrough advances in science and technology alexander rich was cochair of the repligen board of directors until   he was a professor at the massachusetts institute of technology since   considered a founding father of the field of molecular biology he received the national medal of science in   he passed away on april   at  years old     paul schimmel is the ernest and jean hahn professor at the skaggs institute for chemical biology at the scripps research institute he formerly was the john d and catherine t macarthur professor of biochemistry and biophysics in the department of biology at the massachusetts institute of technology  his principal scientific contributions include the discovery of “the second genetic code and expansion of the functional genome     milestones since it’s founding in  repligen has been a leading expert in protein a repligen scientists first cloned the gene for protein a in  and the company introduced the world’s first recombinant form of the ligand in  for many years protein a was sold as a source of nondilutive revenue to support a number of drug development programs that the company was pursuing in  repligen acquired disposable chromatography technology from bioflash commercializing the product as opus® prepacked chromatography columns now the leader and expert in column packing technology in  repligens transformative acquisition of novozymes biopharma ab in  which included additional protein a ligands and growth factor products became the basis of its portfolio of cell culture supplements which quickly doubled its bioprocessing product revenue the strategic decision was made in  to divert repligen’s dual business model to a singularly focused model based on building its bioprocessing business and taking the opportunity to leverage the strength of the biologics market without being tied to the success or failure of any particular drug in  repligen acquired the assets of refine technology through which it gained the xcell™ atf system now a leader in cell culture process intensification in april  repligen acquired atoll gmbh of weingarten germany to provide customers with the broadest selection of prepacked chromatography columns from benchscale to productionscale these products are now opus® pd prepacked columns for process development in december   repligen acquired tangenx™ technology corporation expanding repligens filtration and singleuse portfolios with applications in cell culture harvest purification and final fomulation    copyright  repligen corporation all rights reserved store careers contact legal privacy policy scroll to top careers  repligen homeproductsapplicationsresourcescompanyabout usleadershipoperationscareerscareer opportunitieshistorynewsroomcontactinvestors menu   items  sign in homeproductsupstream solutionsxcell atf systemcell culture supplementsdownstream solutionsopus prepacked columnstangenx tff cassettesprotein a affinity resinsprotein a ligandsanalyticselisa kitsdistributorsstoreapplicationsupstream applicationsperfusionn perfusionhigh density cell bankingmedia optimization  growth factorsdownstream applicationsprepacked columnsmulticolumn chromatographyconcentration and diafiltrationprocess intensificationcontinuous processingintegrated continuous processingresourceseventslibraryquality documentscompanyabout usleadershipoperationscareerscareer opportunitieshistorynewsroomcontactinvestorscorporate profilepress releasesinvestor presentations and eventsleadershipcorporate governancefinancial informationinteractive analyst centersec filingsannual reportsstock informationstock quoteinvestment calculatorownership profileanalyst coveragecontacts and alertsinvestor faq careers with offices and facilities in multiple locations we are always looking for smart driven and enthusiastic individuals to join our growing team  if you do not find current positions that match your qualifications feel free to submit your resume for general consideration collapse all expand all current opportunities repligen headquarters is located in waltham massachusetts usa just outside boston massachusetts  repligen sweden ab is situated in lund in the southern area of the country approximately  km east of copenhagen and in the middle of the “medicon valley” area atoll gmbh is located in weingarten germany current opportunities  benefits in addition to offering competitive salaries and a rewarding dynamic place to work repligen offers industrycompetitive benefits medical insurance dental insurance vision insurance longterm disability insurance flexible spending accounts for medical care and dependent care three weeks vacation paid holidays k plan tuition reimbursement employee assistance program discounted home and auto insurance equity participation in a publicly traded company message to recruiters search firms are essential to our recruitment and staffing efforts and we value the partnerships we have built with our preferred vendors we maintain a preferred vendor list for all regular hires and temporary recruitment across all functions we partner with search firms for specific positions and do not accept unsolicited resumes from agencies if you would like to be added to the preferred vendor list please contact human resources repligen is an equal opportunity employer and complies with all applicable federal state and local laws regarding nondiscrimination repligen provides equal employment opportunities to all employees and applicants for employment without regard to race color religion gender sexual orientation national origin age disability or status as a veteran  copyright  repligen corporation all rights reserved store careers contact legal privacy policy scroll to top continuous processing  repligen homeproductsapplicationsupstream applicationsdownstream applicationsprocess intensificationcontinuous processingintegrated continuous processingresourcescompanyinvestors menu   items  sign in homeproductsupstream solutionsxcell atf systemcell culture supplementsdownstream solutionsopus prepacked columnstangenx tff cassettesprotein a affinity resinsprotein a ligandsanalyticselisa kitsdistributorsstoreapplicationsupstream applicationsperfusionn perfusionhigh density cell bankingmedia optimization  growth factorsdownstream applicationsprepacked columnsmulticolumn chromatographyconcentration and diafiltrationprocess intensificationcontinuous processingintegrated continuous processingresourceseventslibraryquality documentscompanyabout usleadershipoperationscareerscareer opportunitieshistorynewsroomcontactinvestorscorporate profilepress releasesinvestor presentations and eventsleadershipcorporate governancefinancial informationinteractive analyst centersec filingsannual reportsstock informationstock quoteinvestment calculatorownership profileanalyst coveragecontacts and alertsinvestor faq continuous processing think continuous think smallcontinuous bioprocessing allows the constant and uninterrupted processing of materials in parallel production lines view continuous bioprocessing book collapse all expand all industry trends the explosive growth in mabbased biologics the globalization of biomanufacturing and the economic pressures to reduce capital investment cost of development and cost of goods all point to changes in how biopharmaceutical manufacturing plants are designed built and operated  the benefits of continuous processing when applied to biologics production can be paradigmchanging when converting to continuous processing the volumetric productivity of the process increases while the size and volume of equipment decreases  a facility running a continuous process will be significantly smaller than a largescale batch facility thus reducing capital expenses benefits of continuous processing include reduced capital cost and time reduced equipment size deployment of singleuse technology streamlined process flow low cycle times steady state operation consistent product quality increased productivity     review of costs and benefits of  continuous manufacturing and perceived barriers to implementation   by randi hernandez biopharm international april     read continuous manufacturing a changing processing paradigm upstream continuous processing perfusion perfusion or upstream continuous processing has been used since the s high cell density perfusion or xcell™ atf perfusion delivers higher cell concentration and cell viability n perfusion n perfusion refers to the intensification of cell growth in the step prior to the production bioreactor n this process intensification is done using perfusion in the n bioreactor for high cell density seeding of the production bioreactor n or removal of the n bioreactor if the n bioreactor can provide enough cells for the production bioreactor n high density hd cell banking high density hd cell banking is a novel method for seed train optimization using perfusion to intensify cell density and reduce the number of earlystage expansion steps learn more downstream continuous processing multicolumn chromatography a continuous capture chromatography process is the next big challenge for modern bioproduction  multicolumn chromatography operates in continuous mode balancing downstream productivity with upstream titers multicolumn chromatography integrated continuous processing integrated upstream and downstream continuous bioprocesses have the potential to revolutionize bioprocessing leading to significant improvements in process efficiencies manufacturing footprint productivity and cost of goods learn more resources     opinions are those of the authors and not of repligen corporation published   pages view   continuous bioprocessing current practice and future potential the opinions expressed in this book are those of the authors and not of repligen corporation introduction to continuous manufacturingtechnology landscape and trendseric s langer  ronald a rader bioplan associates a brief history of perfusion biomanufacturingjerry shevitz and  john bonhamcarter bioreactor configuration and operationchristel fenge jörg weyand gerhard greller thorsten adamssartorius stedim biotech how to develop a perfusion processvéronique chotteau royal technical university kth case study optimized perfusionshaun eckerle gallus biopharmaceuticals process intensification approaches for cost sensitive protein applicationswillem adriaan de jongh expresion biotechnologies impact of singleuse technology on continuous bioprocessingwilliam g whitford thermo fisher scientific continuous multicolumn chromatography processesmarc bisschops tarpon biosystems continuous processes economic evaluationandrew sinclair  andrew brown biopharm services vision integrating upstream and downstream in a fully continuous facilitytim johnson genzyme selected third party references special report on continuous bioprocessing upstream downstream ready for prime time wuxi biologics expands perfusion cell culture capabilities using atf  system continuous manufacturing a changing processing paradigm developing an integrated continuous bioprocessing platform a discussion with genzymes konstantin konstantinov a novel seedtrain process using high density cell banking a disposable bioreactor and perfusion technologies a brief history of perfusion biomanufacturing how highconcentration cultures will characterize the factory of the future scientific poster tools for intensification of cell culture production and continuous downstream processing  copyright  repligen corporation all rights reserved store careers contact legal privacy policy scroll to top company  repligen homeproductsapplicationsresourcescompanyabout usleadershipoperationscareershistorynewsroomcontactinvestors menu   items  sign in homeproductsupstream solutionsxcell atf systemcell culture supplementsdownstream solutionsopus prepacked columnstangenx tff cassettesprotein a affinity resinsprotein a ligandsanalyticselisa kitsdistributorsstoreapplicationsupstream applicationsperfusionn perfusionhigh density cell bankingmedia optimization  growth factorsdownstream applicationsprepacked columnsmulticolumn chromatographyconcentration and diafiltrationprocess intensificationcontinuous processingintegrated continuous processingresourceseventslibraryquality documentscompanyabout usleadershipoperationscareerscareer opportunitieshistorynewsroomcontactinvestorscorporate profilepress releasesinvestor presentations and eventsleadershipcorporate governancefinancial informationinteractive analyst centersec filingsannual reportsstock informationstock quoteinvestment calculatorownership profileanalyst coveragecontacts and alertsinvestor faq company our mission is to inspire advances in bioprocessing as a trusted partner in the production of biologic drugs that improve human health worldwide focused on cost and process efficiencies we deliver innovative technologies and solutions that help set new standards in bioprocessing collapse all expand all about us inspiring advances in bioprocessing repligen is a trusted partner in upstream process intensification and downstream prepacked chromatography and filtration  focused on cost and process efficiencies our people and our technologies help meet critical bioprocessing demands worldwide  as the recognized  global leader in protein a manufacturing repligens protein a affinity ligands are routinely used to purify most of the world’s monoclonal antibodies  corporate profile leadership our leadership team represents a relevant depth and diversity of individuals with the experience and shared vision to transform bioproduction our management team is guiding repligen to be a bestinclass organization within the bioprocessing segment of the life sciences industry  meet the leaders operations repligen manufactures products for the biopharmaceutical industry in iso  compliant production facilities we focus on continuous improvement business continuity and risk mitigation operations careers we are always looking for smart driven and enthusiastic additions to our growing team please view our current openings  if you do not find current positions that match your qualifications feel free to submit your resume for general consideration repligen offices and facilities are located in waltham massachusetts usa  headquarters lund sweden weingarten germany shrewsbury massachusetts usa careers history founded in  by two pioneering scientists repligen is a leader today in protein a ligand manufacturing and has become a trusted partner in providing innovative technologies and solutions that are setting new standards for efficiency and productivity in the manufacture of biologic drugs  history newsroom read or download repligen press releases announcements industry articles about repligen and press contact information repligen announcements repligen in the news press contact newsroom contact repligen corporation  headquarters seyon streetbuilding  suite waltham ma usa all locations phone tollfree fax     copyright  repligen corporation all rights reserved store careers contact legal privacy policy scroll to top products  repligen  upstream downstream analytics homeproductsupstream solutionsdownstream solutionsanalyticsdistributorsstoreapplicationsresourcescompanyinvestors menu   items  sign in homeproductsupstream solutionsxcell atf systemcell culture supplementsdownstream solutionsopus prepacked columnstangenx tff cassettesprotein a affinity resinsprotein a ligandsanalyticselisa kitsdistributorsstoreapplicationsupstream applicationsperfusionn perfusionhigh density cell bankingmedia optimization  growth factorsdownstream applicationsprepacked columnsmulticolumn chromatographyconcentration and diafiltrationprocess intensificationcontinuous processingintegrated continuous processingresourceseventslibraryquality documentscompanyabout usleadershipoperationscareerscareer opportunitieshistorynewsroomcontactinvestorscorporate profilepress releasesinvestor presentations and eventsleadershipcorporate governancefinancial informationinteractive analyst centersec filingsannual reportsstock informationstock quoteinvestment calculatorownership profileanalyst coveragecontacts and alertsinvestor faq products as a leader in protein a manufacturing prepacked chromatography and cell retention technologies repligen is helping to set new standards in bioprocessing upstream solutions collapse all expand all xcell™ atf system simplify and intensify upstream bioprocessingthe xcell™ atf system a cell retention device available in singleuse or stainless steel format attached to a bioreactor delivers high cell density and process intensification xcell™ atf system cell culture supplements recombinant and animalfree repligen cell culture supplements provide the benefits of serumderived supplementation while maintaining an animalfree process cell culture supplements downstream solutions collapse all expand all opus® prepacked chromatography columns leader of the packwith the broadest range from benchscale to productionscale opus® columns are readytouse prepacked alternatives to selfpacked columns opus® prepacked columns tangenx™ tff cassettes reliable scalable and costeffective tangenx™ solutions enable efficient concentration and diafiltration  tangenx™ tff cassettes protein a affinity resins protein a ligands protein a resins from the leading manufacturer of rprotein a ligandsprotein a affinity resins from repligen help you optimize process economics while maintaining industrystandard performance protein a affinity resinsprotein a affinity resins protein a ligands leader in protein a ligand manufacturing since most of the worlds commercial monoclonal antibodies are purified using native and recombinant protein a ligands manufactured by repligen protein a ligands analytics collapse all expand all elisa kits elisa kits deliver fast reliable and reproducible quantitation of leached protein a mabselect sure™ ligand and long®r igfi elisa kits  copyright  repligen corporation all rights reserved store careers contact legal privacy policy scroll to top newsroom  repligen homeproductsapplicationsresourcescompanyabout usleadershipoperationscareershistorynewsroomcontactinvestors menu   items  sign in homeproductsupstream solutionsxcell atf systemcell culture supplementsdownstream solutionsopus prepacked columnstangenx tff cassettesprotein a affinity resinsprotein a ligandsanalyticselisa kitsdistributorsstoreapplicationsupstream applicationsperfusionn perfusionhigh density cell bankingmedia optimization  growth factorsdownstream applicationsprepacked columnsmulticolumn chromatographyconcentration and diafiltrationprocess intensificationcontinuous processingintegrated continuous processingresourceseventslibraryquality documentscompanyabout usleadershipoperationscareerscareer opportunitieshistorynewsroomcontactinvestorscorporate profilepress releasesinvestor presentations and eventsleadershipcorporate governancefinancial informationinteractive analyst centersec filingsannual reportsstock informationstock quoteinvestment calculatorownership profileanalyst coveragecontacts and alertsinvestor faq newsroom collapse all expand all announcements june   repligen corporation and spectrum inc to join forces december   repligen acquires tangenx technology corporation october   repligen hires ralf kuriyel as senior vice president of research and development october   repligen launches singleuse xcell™ atf system for bioprocess intensification april   repligen acquires atoll gmbh march   repligen forms scientific advisory board recognized experts in bioprocessing to provide input on product innovation and portfolio expansion for repligen february   repligen announces extension of long term supply agreement for protein a  reaffirms position as strategic supplier of affinity ligands to ge healthcare september   repligen appoints glenn p muir to board of directors february   repligen completes expansion of us facility includes stateoftheart manufacturing for atf system january   repligen corporation names tony hunt as next chief executive officerwalter c herlihy to retire effective may   annual meeting of stockholders in the news june   repligen agrees to buy spectrum for  million by robert weismanboston globe march   repligen to up column production on back of milestone year for chromatography by dan stantonbiopharma reporter december   repligen adds singleuse filtration technology through tangenx acquisition by dan stantonbiopharma reporter december   repligen pays  million to buy tangenx technology by robert weismanthe boston globe november   repligen resin recovery feature a ‘differentiator’ in chromatography space by dan stantonbiopharma reporter october   repligen launches singleuse version of its cell retention tech by dan stantonbiopharma reporter may   special report on continuous bioprocessing upstream downstream ready for prime time by angelo depalmabioprocessing international may   repligen to expand chromatography column production capacity in us and europe by dan stantonbiopharma reporter april   prepacked chromatography columns evaluation for use in pilot and largescale bioprocessing by shaun grier and saani yakububioprocess international february   repligen extends protein a ligand supply deal with ge healthcare by dan stantonbiopharma reporter january  february  opus® columns win design excellence awards winner  if  design excellence award  product winner  good design  award for design excellence  industry notable mention   core award for design excellence  commercial equipment fall  wuxi biologics expands perfusion cell culture capabilities in  using atf  system november   announcing the  north america technology fast ™ rankings annual ranking of fastest growing north america companies deloitte us october   the lowdown on scale­up mismatches many of the scaleup mismatches can be avoided with careful planning by angelo depalma phdgenetic engineering news september   repligen now a bioprocess product firm onetime therapeutics player bets future on working as supplier to bioprocess companies by gail duttongenetic engineering news april   repligen boasts about the size of its column by dan stantonbiopharma reporter april   continuous processing a changing processing paradigm by randi hernandezbiopharm international press contact sondra newmansenior director investor relations phone tollfree fax pressrepligencom download repligen logo see all press releases  copyright  repligen corporation all rights reserved store careers contact legal privacy policy scroll to top repligen  inspiring advances in bioprocessing homeproductsapplicationsresourcescompanyinvestors menu   items  sign in homeproductsupstream solutionsxcell atf systemcell culture supplementsdownstream solutionsopus prepacked columnstangenx tff cassettesprotein a affinity resinsprotein a ligandsanalyticselisa kitsdistributorsstoreapplicationsupstream applicationsperfusionn perfusionhigh density cell bankingmedia optimization  growth factorsdownstream applicationsprepacked columnsmulticolumn chromatographyconcentration and diafiltrationprocess intensificationcontinuous processingintegrated continuous processingresourceseventslibraryquality documentscompanyabout usleadershipoperationscareerscareer opportunitieshistorynewsroomcontactinvestorscorporate profilepress releasesinvestor presentations and eventsleadershipcorporate governancefinancial informationinteractive analyst centersec filingsannual reportsstock informationstock quoteinvestment calculatorownership profileanalyst coveragecontacts and alertsinvestor faq inspiring advances in bioprocessing repligen and spectrum to join forces repligen has entered into a definitive merger agreement with spectrum inc a market leader in bioprocess filtration with expertise in hollow fiber technology the deal will significantly expand repligen’s filtration product offerings and extend its reach into new applications and geographies about spectrum                          announcement opus® columns for process development formerly atoll columns are used for screening process validation including viral clearance scaleup and sample preparationlearn morelearn more leader of the pack atoll columns are now opus® columns for process development × user info access login to view this content email password login not registered register  forgot your password close   achieve  cell retention and labtoproduction scalability without the need for autoclave sterilization learn more xcell™ atf singleuse is here events sep   biotech weekboston ma   see all events opus® r and r prepacked columns feature an innovative unpacking port for simple resin removallearn morelearn more ultimate flexibility from prepacked to unpacked opus® r and opus® r columns stock quote rgenas of  am et investors jul   repligen to report second quarter  financial results jun   repligen corporation prices public offering of shares of common stock investors   tangenx™ sius™ singleuse cassettes are the first purposebuilt singleuse cassettes for tangential flow filtrationlearn more tangenx™ solutions for tangential flow filtration  copyright  repligen corporation all rights reserved store careers contact legal privacy policy scroll to top corporate news blog  repligen corp and spectrum merge to form leader in filtration for bioprocessing industryhomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets open in  hr  minssp futures dow futures nasdaq futures corporate news blog  repligen corp and spectrum merge to form leader in filtration for bioprocessing industryaccesswirejune  reblogsharetweetshareresearch desk lineup biopharmx corporation post earnings coverage london uk  accesswire  june    protrader daily takes a look at the latest corporate events and news making the headlines for waltham massachusetts based repligen corp nasdaq rgen following which we have published a free report that can be viewed by signing up at httpprotraderdailycomoptinsymbolrgen the company announced on june   that it had signed a merger agreement with spectrum inc a privatelyowned company the value of cash plus stock deal is approximately  million repligen expects to accelerate the growth of its filtration business with this acquisition and establish itself as a leader in the bioprocessing technology business for immediate access to our complimentary reports including todays coverage register for free now athttpprotraderdailycomregisterdiscover more of our free reports coverage from other companies within the biotechnology industry protd has currently selected biopharmx corporation nyse mkt bpmx for duediligence and potential coverage as the company announced on june   its financial results for q  which ended on april   and also discussed the progress of its clinical research tune in to our site to register for a free membership and be among the early birds that get our report on biopharmx corporation when we publish itat protd we make it our mission to bring you news that matter about the stock you follow today our research desk covers a blog story on rgen also brushing on bpmx go directly to your stock of interest and access todays free coverage athttpprotraderdailycomoptinsymbolrgenhttpprotraderdailycomoptinsymbolbpmxcommenting on the merger with spectrum tony j hunt president and ceo of repligen saidthis is a pivotal transaction for repligen that meets all of our acquisition criteria and is a major step forward in building repligen as a global leader in bioprocessing and achieving our longterm financial goals we look forward to joining forces with the spectrum team with whom we are closely aligned in our commitments to delivering innovative products and exceptional customer serviceroy eddleman chairman and ceo of spectrum addedspectrum has developed worldclass products delivered with firstclass customer service repligen has a proven track record of unlocking additional value and accelerating growth in previous acquisitions i am excited for the opportunities our combined businesses will bring to our customers employees and other stakeholdersdetails of the merger agreementrepligens offer of  million to acquire spectrum includes  million in cash and  repligens shares the transaction is expected to be completed in q  and is subject to expiration or termination of the waiting period under the hartscottrodino hsr antitrust improvements act of  regulatory approvals and other closing conditionsrepligen plans to finance the transaction with available cash on hand of approximately  million on march   the company may acquire additional funds via debt from jpmorgan chase bank nathe company has clarified that it has excluded certain items like gains or losses that are either isolated or cannot be expected to occur again with any regularity or predictability including due to the impact of acquisitions tax provisionsbenefits related to previous items benefits from tax credit carry forwards and the impact of tax audits or events would be excluded the exclusion is aimed at addressing the financial impact of the acquisition and since they are outside the companys normal operations and in some cases it is difficult to forecast accurately for the futurehow repligen benefits from the mergerthe acquisition holds great financial value for repligen the deal is expected to add approximately  million to  million to repligens revenue for fy for fy repligen expects the deal to contribute approximately  million to  million in incremental revenue adjusted for intercompany sales the deal is expected to be accretive to the companys earnings both gaap and eps in fy the deal is expected to result in total synergies of  million to  million within next three years out of this revenue synergies would be approximately  million to  million and more than  million in cost synergiesread morespectrums portfolio of bioprocess filtration with hollow fiber hf tangential flow filtration tff products and associated systems and consumables will add to the existing repligens product range this will enable repligen to improve its market position and range of filtration productsrepligens xcell™ atf filtration portfolio requires hollow fiber filters on a consumable basis and is currently outsourced by the company to oems with this acquisition spectrums hollow fiber tff products and associated rd expertise will automatically solve this problem and expands repligens ability to meet customers needs at a single locationthe acquisition allows repligen to expand its reach to new areas beyond its current monoclonal antibody production into a vaccine recombinant protein and gene therapy production it will be able to expand to spectrums markets which include vaccine recombinant protein and gene therapy markets where it can tap on cross selling opportunities for its chromatography and filtration productsrepligen will also be able to expand its global footprint in markets like the us europe and asia where spectrum has an established sales and distribution networkabout spectrum incrancho dominguez california based spectrum was founded in  and is a diversified filtration company with a distinguished range of hollow fiber cartridges benchtop to commercial scale filtration and perfusion systems and an expansive portfolio of singleuse solutions the companys products are used for the filtration isolation purification and concentration of monoclonal and cell therapies the company offers both standard and customized solutions for its bioprocessing customers the company has a wide variety of over  products for the bioprocess filtration and continuous manufacturing industrythe total revenue for spectrum for fy was approximately  million and  of this revenue was generated from its filtration product portfoliothe company has manufacturing units at rancho dominguez california and at houston and dallas in texas and international sales offices in breda netherlands and otsucity shiga japanlast close stock review on friday june   the stock closed the trading session at  surging  from its previous closing price of  a total volume of  thousand shares have exchanged hands which was higher than the month average volume of  thousand shares repligens stock price skyrocketed  in the last three months  in the past six months and  in the previous twelve months furthermore since the start of the year shares of the company have soared  the stock is trading at a pe ratio of  at fridays closing price the stocks net capitalization stands at  billion protrader dailyprotrader daily protd produces regular sponsored and nonsponsored reports articles stock market blogs and popular investment newsletters covering equities listed on nyse and nasdaq and canadian stocks protd has two distinct and independent departments one department produces nonsponsored analyst certified content generally in the form of press releases articles and reports covering equities listed on nyse and nasdaq and the other produces sponsored content in most cases not reviewed by a registered analyst which typically consists of compensated investment newsletters articles and reports covering listed stocks and microcaps such sponsored content is outside the scope of procedures detailed belowprotd has not been compensated directly or indirectly for producing or publishing this documentpress release proceduresthe nonsponsored content contained herein has been prepared by a writer the author and is fact checked and reviewed by a third party research service company the reviewer represented by a credentialed financial analyst for further information on analyst credentials please email contactprotraderdailycom rohit tuli a cfa® charterholder the sponsor provides necessary guidance in preparing the document templates the reviewer has reviewed and revised the content as necessary based on publicly available information which is believed to be reliable content is researched written and reviewed on a reasonableeffort basis the reviewer has not performed any independent investigations or forensic audits to validate the information herein the reviewer has only independently reviewed the information provided by the author according to the procedures outlined by protd protd is not entitled to veto or interfere in the application of such procedures by the thirdparty research service company to the articles documents or reports as the case may be unless otherwise noted any content outside of this document has no association with the author or the reviewer in any wayno warrantyprotd the author and the reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error mistake or shortcoming no liability is accepted whatsoever for any direct indirect or consequential loss arising from the use of this document protd the author and the reviewer expressly disclaim any fiduciary responsibility or liability for any consequences financial or otherwise arising from any reliance placed on the information in this document additionally protd the author and the reviewer do not  guarantee the accuracy timeliness completeness or correct sequencing of the information or  warrant any results from use of the information the included information is subject to change without noticenot an offeringthis document is not intended as an offering recommendation or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only please read all associated disclosures and disclaimers in full before investing neither protd nor any party affiliated with us is a registered investment adviser or brokerdealer with any agency or in any jurisdiction whatsoever to download our reports read our disclosures or for more information visit httpprotraderdailycomdisclaimercontactfor any questions inquiries or comments reach out to us directly if youre a company we are covering and wish to no longer feature on our coverage list contact us via email andor phone between  edt to  edt from monday to friday at email contactprotraderdailycomphone number  office address mainzer landstrasse  frankfurt am main germany cfa® and chartered financial analyst® are registered trademarks owned by cfa institutesource protrader dailyreblogsharetweetsharerecently viewedyour list is emptywhat to read nexthow microsoft wants to bring broadband to rural americansyahoo financezuckerberg wifes ambitious secret finally exposedunewzmesponsoredsean hannity responds to claim he ran up a  tab at trumps hotel after flying in a yearold lobster from mainebusiness insidertrump’s unwitting legacy could be universal health coverageyahoo financemattis was on vacation when trump tweeted transgender ban and he was reportedly appalled by itbusiness insiderengineer finds pattern makes millions in stocksmoney morningsponsoredvirgin atlantic founder sir richard branson sells pc stake in airline for £m as part of new tieup with air franceklmthe telegraphtwitter is only famous now because of president trump nyse traderyahoo finance videogdp — what you need to know in markets on fridayyahoo financethis will be in everyones household by banyan hillsponsoredamazon wobble ripples across world stock marketsreuterswhite house comms director scaramucci im not steve bannon im not trying to suck my own ckbusiness insiderrepublicans kill the border taxyahoo financea pennycrypto miracle making some americans richagora financialsponsoredconocophillips trims capex after posting quarterly lossreutersamazon could be the first trillion dollar company nyse traderyahoo finance videorussia orders cut in us diplomats in reaction to sanctionsdirk gosh i hope this doesnt lead russia to deny america of all the russian cars russian electronics russian textiles and all other russian products that we consume oh waitwe dont theyre irrelevantjoin the conversation   repligen  inspiring advances in bioprocessing homeproductsapplicationsresourcescompanyinvestors menu   items  sign in homeproductsupstream solutionsxcell atf systemcell culture supplementsdownstream solutionsopus prepacked columnstangenx tff cassettesprotein a affinity resinsprotein a ligandsanalyticselisa kitsdistributorsstoreapplicationsupstream applicationsperfusionn perfusionhigh density cell bankingmedia optimization  growth factorsdownstream applicationsprepacked columnsmulticolumn chromatographyconcentration and diafiltrationprocess intensificationcontinuous processingintegrated continuous processingresourceseventslibraryquality documentscompanyabout usleadershipoperationscareerscareer opportunitieshistorynewsroomcontactinvestorscorporate profilepress releasesinvestor presentations and eventsleadershipcorporate governancefinancial informationinteractive analyst centersec filingsannual reportsstock informationstock quoteinvestment calculatorownership profileanalyst coveragecontacts and alertsinvestor faq inspiring advances in bioprocessing repligen and spectrum to join forces repligen has entered into a definitive merger agreement with spectrum inc a market leader in bioprocess filtration with expertise in hollow fiber technology the deal will significantly expand repligen’s filtration product offerings and extend its reach into new applications and geographies about spectrum                          announcement opus® columns for process development formerly atoll columns are used for screening process validation including viral clearance scaleup and sample preparationlearn morelearn more leader of the pack atoll columns are now opus® columns for process development × user info access login to view this content email password login not registered register  forgot your password close   achieve  cell retention and labtoproduction scalability without the need for autoclave sterilization learn more xcell™ atf singleuse is here events sep   biotech weekboston ma   see all events opus® r and r prepacked columns feature an innovative unpacking port for simple resin removallearn morelearn more ultimate flexibility from prepacked to unpacked opus® r and opus® r columns stock quote rgenas of  am et investors jul   repligen to report second quarter  financial results jun   repligen corporation prices public offering of shares of common stock investors   tangenx™ sius™ singleuse cassettes are the first purposebuilt singleuse cassettes for tangential flow filtrationlearn more tangenx™ solutions for tangential flow filtration  copyright  repligen corporation all rights reserved store careers contact legal privacy policy scroll to top analytics  repligen homeproductsupstream solutionsdownstream solutionsanalyticselisa kitsdistributorsstoreapplicationsresourcescompanyinvestors menu   items  sign in homeproductsupstream solutionsxcell atf systemcell culture supplementsdownstream solutionsopus prepacked columnstangenx tff cassettesprotein a affinity resinsprotein a ligandsanalyticselisa kitsdistributorsstoreapplicationsupstream applicationsperfusionn perfusionhigh density cell bankingmedia optimization  growth factorsdownstream applicationsprepacked columnsmulticolumn chromatographyconcentration and diafiltrationprocess intensificationcontinuous processingintegrated continuous processingresourceseventslibraryquality documentscompanyabout usleadershipoperationscareerscareer opportunitieshistorynewsroomcontactinvestorscorporate profilepress releasesinvestor presentations and eventsleadershipcorporate governancefinancial informationinteractive analyst centersec filingsannual reportsstock informationstock quoteinvestment calculatorownership profileanalyst coveragecontacts and alertsinvestor faq analytics elisa kits elisa kits deliver fast reliable and reproducible quantitation of leached protein a mabselect sure™ ligand and long®r igfi elisa kits  copyright  repligen corporation all rights reserved store careers contact legal privacy policy scroll to top